← Back
Clinical Medicine and Surgery I · Exam 6 · Class of 2028

CMS I Exam 6 Cram Sheet

The study focus the lecturer posted comes first (Lectures 37–38), then criteria, scores and classifications: one table per set from the slides, each with a labeled memory aid. Respiratory Block Exam I, condensed from the Exam 6 study guide. Lectures covered: 33 (oxygen delivery), 34 (acid-base part I), 35 (asthma), 36 (chronic obstructive pulmonary disease), 37 (respiratory infections and vaccines), 38 (mycobacterial infections including tuberculosis). Each lecture opens with a gold card of what its lecturer stressed on the recording (starred); every fact still comes from the slides.

How to use this: this is a condensed, night-before-the-exam reference, not a replacement for the full study guide — it assumes you've already learned the material and just need the highest-yield facts at a glance. If a term feels unfamiliar, go back to the full guide for the explanation.

Study Focus: Respiratory Infections (slide 127)Study focus · Lecture 37 · slide 127 (about 20 questions)

Focus pointKnow this
PREVENTION & VACCINES
Influenza product selectionYearly for everyone 6 months or older without a contraindication; 65 or older: preferentially high-dose, adjuvanted or recombinant; pregnancy: inactivated or recombinant, avoid live attenuated; egg allergy: routine safety measures only
Respiratory syncytial virus (RSV) eligibilityOne dose: all adults 75 or older, and 50–74 at increased risk; not an annual vaccine
Pneumococcal sequencingConjugate-naive eligible adult: PCV20 or PCV21 alone completes the series; PCV15 is followed by PPSV23, usually 1 year or more later (PCV = pneumococcal conjugate vaccine, PPSV23 = 23-valent polysaccharide vaccine)
BRONCHITIS & STEWARDSHIP
Bronchitis or pneumonia?Uncomplicated bronchitis is clinical and usually viral; abnormal vital signs, hypoxemia, fever or focal consolidation → chest film for pneumonia
Sputum colorGreen or yellow sputum does not justify antibiotics; no routine antibiotics for uncomplicated bronchitis
COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Confirmation and site of careChest radiograph confirms (lung ultrasound with expertise); Pneumonia Severity Index plus judgment for outpatient versus general ward; severe CAP gets urgent intensive care-level assessment
Severe CAPVasopressor-dependent shock, mechanical ventilation, or 3 or more minor criteria
Outpatient regimensNo comorbidities: amoxicillin or doxycycline (macrolide alone only if pneumococcal resistance below 25%). Comorbidities: amoxicillin-clavulanate, cefpodoxime or cefuroxime plus azithromycin or doxycycline, or a respiratory fluoroquinolone
Resistant coverageMethicillin-resistant Staphylococcus aureus or Pseudomonas coverage only for validated risk (prior respiratory isolation, recent hospitalization with intravenous antibiotics)
HOSPITAL-ACQUIRED (HAP) & VENTILATOR-ASSOCIATED (VAP) PNEUMONIA, ASPIRATION
Timing, cultures, antibiogramHAP: 48 hours or more after admission; VAP: more than 48 hours after intubation. Respiratory cultures first, then empiric therapy by the local antibiogram (cefepime or piperacillin-tazobactam); do not delay care in unstable patients
De-escalationNarrow or stop as cultures and the course clarify; usually 7 days
Pneumonitis vs aspiration pneumoniaPneumonitis: sterile chemical injury, support, no prophylactic antibiotics when bacterial infection is not suspected. Pneumonia: infection, CAP or HAP regimen by setting. Anaerobic coverage only for abscess or empyema
OPPORTUNISTIC & ATYPICAL
Pneumocystis jirovecii pneumonia (PJP): sampling and PCRInduced sputum or bronchoalveolar lavage (expectorated sputum: poor sensitivity); polymerase chain reaction (PCR) is highly sensitive but can detect colonization
Steroid thresholdsHuman immunodeficiency virus (HIV)-associated PJP: adjunctive corticosteroids if room-air arterial oxygen below 70 mm Hg or alveolar-arterial oxygen gradient 35 mm Hg or more
Histoplasmosis by severityMild acute, immunocompetent: often observe, no antifungal; prolonged or progressive, or higher-risk host: consider itraconazole; severe or disseminated: specialist-led amphotericin-based induction; chronic cavitary: azole, usually 12 months or more
PsittacosisBird exposure; respiratory nucleic acid test; doxycycline preferred (macrolide with infectious disease input if tetracyclines are unsuitable)
INFLUENZA & COVID-19
Negative rapid influenza testDoes not exclude influenza, especially with high activity; do not withhold indicated antivirals
High-risk influenzaOseltamivir promptly, even after 48 hours
COVID-19 pathwaysNo hypoxemia, high-risk outpatient: nirmatrelvir/ritonavir within 5 days or 3-day remdesivir within 7 days; no systemic steroids unless another indication exists. Hypoxemic inpatient: dexamethasone, consider remdesivir; baricitinib or tocilizumab for rapid progression; venous thromboembolism prophylaxis
Best study methodFor each topic, practice the same five decisions: diagnosis, severity/site of care, the test that changes management, first-line treatment, and when to withhold or narrow therapy

Study Focus: Tuberculosis & Nontuberculous Mycobacteria (slide 41)Study focus · Lecture 38 · slide 41 (about 10 questions)

Focus pointKnow this
Smear ≠ speciesA positive acid-fast smear cannot tell tuberculosis from nontuberculous mycobacteria; confirm the species with molecular testing and culture
Right infection testPrefer the interferon-gamma release assay after BCG (bacille Calmette-Guérin); in human immunodeficiency virus (HIV) infection or a recent close contact, skin test induration 5 mm or more is positive and needs evaluation for active disease
Rule out active tuberculosis firstSkin and blood tests show infection, not latent versus active: clinical evaluation and chest imaging before preventive therapy
Right specimens3 sputum specimens, 8–24 hours apart, 1 early morning; acid-fast smear and culture plus 1 rapid molecular test
Exposure and suspicionRepeat an early negative test 8–10 weeks after the last exposure; suspected pulmonary tuberculosis: immediate airborne isolation and tuberculosis-program coordination
Mycobacterium avium complex (MAC)One isolate is not enough: symptoms, imaging and usually 2 or more same-species sputum cultures; azithromycin + ethambutol + a rifamycin for 12 months or more after culture conversion
Memory aid

The slide’s numbers, in order: 5 · 3 · 8–24 · 1 · 8–10 · 2+ · 12+.

5 mm skin test cut-off in HIV or a recent close contact3 sputum specimens8–24 hours between specimens1 early-morning specimen (and 1 rapid molecular test)8–10 weeks after the last exposure to repeat an early negative test2+ usually 2 or more same-species sputum cultures for MAC12+ at least 12 months of MAC treatment after culture conversion

Where it breaks: The 1 stands for two things on the slide: one early-morning sample and one rapid molecular test.

Oxygen Therapy: Indications, Benefits & RisksCriteria · Lecture 33 · slide 3

SideWhat slide 3 lists
IndicationsHypoxia · acute medical/surgical needs (perioperative/postoperative period) · respiratory conditions (carbon monoxide poisoning) · special indications: air hunger, cluster headache
BenefitsCorrection of hypoxia · symptom relief · therapeutic benefits
RisksHypercapnia/carbon dioxide retention · fire hazard! · mucosal irritation · vasoconstriction (remember, not given in myocardial infarction unless oxygen saturation < 91%)
Slide 3 gives the myocardial infarction cut-off as below 91%; the slide’s 91% is the value tested.
Memory aid

Hypoxic Patients Can Accept Cannulas — but Fire Has Many Victims.

H HypoxiaP Perioperative/postoperative (acute medical or surgical need)C Carbon monoxide poisoningA Air hungerC Cluster headacheF Fire hazardH Hypercapnia (carbon dioxide retention)M Mucosal irritationV Vasoconstriction: not in myocardial infarction unless saturation is below 91%

Where it breaks: The benefits row (correction of hypoxia, symptom relief, therapeutic benefit) is not in the aid. Air hunger and cluster headache are listed apart, as the special indications.

Home Oxygen Qualification (Medicare)Criteria · Lecture 33 · slides 5–6

Situation (slide 6)Qualifying criteria (arterial oxygen = partial pressure of oxygen in arterial blood)Result
Resting (room air)Arterial oxygen ≤ 55 mm Hg or saturation ≤ 88%Group I qualification
Resting (conditional)Arterial oxygen 56–59 mm Hg or saturation = 89% + evidence of pulmonary hypertension, cor pulmonale, or hematocrit > 56%Group II qualification
During sleepArterial oxygen ≤ 55 mm Hg or saturation ≤ 88% with a ≥ 5% drop from baselineQualifies for nocturnal oxygen
During exertionArterial oxygen ≤ 55 mm Hg or saturation ≤ 88% during exercise and improves with oxygenQualifies for ambulatory oxygen
RecertificationGroup I: 12 months · Group II: 3 monthsRepeat testing required
Slide 5: document hypoxia by arterial blood gas or pulse oximetry during rest, exertion and/or sleep, performed at the time of need; saturation values are on room air. Slide 5 names the Group II blood finding “polycythemia” and lists only saturation for sleep and exertion; slide 6’s picture gives hematocrit > 56% and adds the arterial oxygen alternative.
Memory aid

55 and 88 qualify outright (Group I, renew yearly); 56–59 or 89 need a second finding (Group II, renew every 3 months).

55 / 88 Group I at rest: arterial oxygen 55 or less, or saturation 88% or less56–59 / 89 + sign Group II: plus pulmonary hypertension, cor pulmonale or hematocrit above 56%Sleep 88% or less with a drop of 5% or moreExertion 88% or less and improves with oxygen12 vs 3 Group I recertifies at 12 months, Group II at 3

Where it breaks: The sleep and exertion rows use the Group I numbers but add a condition: a drop of 5% or more from baseline during sleep, improvement with oxygen during exertion.

Nasal Cannula: Liters to Oxygen FractionCriteria · Lecture 33 · slides 9, 11

Flow (L/min)Fraction of inspired oxygen (slide 9)
Room air.21 or 21%
1.24 or 24%
2.28 or 28%
3.32 or 32%
4.36 or 36%
5.40 or 40%
6.44 or 44%
Slide 11: low flow device, most commonly used in mild hypoxia; each 1 L increase adds 4%; the knob turns above 6 L/min but the fraction maxes out at 44%. Slide 9: humidity is used with flow rates greater than 4 L/min. Slide 9 prints the range as “.24% to .44%”; its own list shows .24 to .44, that is 24% to 44%.
Memory aid

Start at 20 and add 4 per liter: 24, 28, 32, 36, 40, 44.

21 room air+4 each liter adds 4%6 L = 44% the ceiling: no gain above 6 L/min> 4 L add humidity

Where it breaks: The count starts from 20, not room air’s 21: 1 L/min is 24%, not 25%.

Simple Mask: Setting to Oxygen FractionCriteria · Lecture 33 · slide 13

Oxygen setting (slide 13)Fraction of inspired oxygen
5–6 L/min35%
6–7 L/min40%
7–8 L/min50%
Slide 13: low flow device, set between 5 and 10 L/min, used in mild to moderate respiratory distress. The slide 20 table gives the simple mask .35–.50 at 5–10 L/min.
Memory aid

35, 40, 50: the mask’s three steps sit between 5 and 8 L/min.

5–6 35%6–7 40%7–8 50%

Where it breaks: The steps are uneven (+5, then +10), and the mask starts at 5 L/min, inside the cannula’s 1–6 L/min range.

Oxygen Delivery Devices ComparedCriteria · Lecture 33 · slides 8–9, 11, 13–17, 19–20

DeviceFlow typeFraction (slide 20)Flow (slide 20)Delivered fraction (slide 8)
Nasal cannulaLow flow (slide 11).24–.44 (slide 9)1–6 L/min (slide 9)Varies with respiration rate, inspiratory flow and tidal volume
Simple maskLow flow (slide 13).35–.505–10 L/minVaries with respiration rate, inspiratory flow and tidal volume
Partial rebreather mask—.40–.70At least 10 L/minVaries with patient demand
Non-rebreather maskLow flow device, but with high fraction (slide 15).60–1.0At least 10 L/min (slide 15: 10–15 L/min = 60–100%)Varies with patient demand
Venturi maskHigh flow (slide 16).24–.50Variable (slide 16: 4–10 L/min)Precise: the port chosen sets the fraction (slide 16)
Air-entrainment nebulizer—.21–1.0VariableFixed (air entrainment): does not fluctuate
Partial rebreather: slide 14 says it delivers 60–80%; the slide 20 table says .40–.70. Not tested either way.
Air-entrainment nebulizer (aerosol mask, open face mask, T-piece, tracheostomy collar): slide 17 says .28–1.0, can deliver higher but not recommended above .50; slide 20 says .21–1.0.
Slide 17: non-rebreather flow must prevent bag collapse on inspiration; Venturi total flow should be higher than inspiratory demand. Non-rebreather = severely hypoxic patients still ventilating well (slide 15); Venturi = often chronic obstructive pulmonary disease, for precision (slide 16).
Memory aid

Venturi is Precise and the entrainment nebulizer Fixed; everything else Varies. Ceiling ladder: cannula 44, mask 50, partial 70, non-rebreather 100.

Cannula .24–.44 at 1–6 L/minSimple mask .35–.50 at 5–10 L/minPartial rebreather .40–.70, at least 10 L/minNon-rebreather .60–1.0, at least 10 L/minVenturi .24–.50, precise (ports), high flowAir-entrainment nebulizer .21–1.0, fixed, not above .50 (slide 17)

Where it breaks: The Venturi mask and the air-entrainment nebulizer sit off the ladder: the Venturi mask is set precisely by its ports (slide 16), and the air-entrainment system gives a fixed fraction (slide 8).

Normal Blood Gas ValuesCriteria · Lecture 34 · slides 3, 5–6

Measurement (slide 6)Arterial bloodVenous blood
pH (range)7.40 (7.35–7.45)7.36 (7.31–7.41)
Partial pressure of oxygen, mm Hg (decreases with age)80–10030–50
Partial pressure of carbon dioxide, mm Hg36–4440–52
Oxygen saturation, % (decreases with age)> 9560–85
Bicarbonate, mEq/L22–2622–28
Base difference (deficit/excess)−2 to +2−2 to +2
Slide 3: acidemia = pH < 7.35, alkalemia = pH > 7.45; acidosis and alkalosis are the pathologic conditions behind them. Slide 5 repeats the arterial pH, carbon dioxide and bicarbonate ranges.
Memory aid

Arterial gas = 7.40, 40, 24, each give or take a little: pH ± 0.05, carbon dioxide ± 4, bicarbonate ± 2.

7.40 ± 0.05 pH 7.35–7.4540 ± 4 carbon dioxide 36–44 mm Hg24 ± 2 bicarbonate 22–26 mEq/L80–100 arterial oxygen pressure> 95 arterial saturation± 2 base difference, arterial and venous alike

Where it breaks: The venous column does not follow the pattern: lower pH, higher carbon dioxide, far lower oxygen. Oxygen pressure and saturation fall with age.

pH Cut-OffsCriteria · Lecture 34 · slides 3, 8

pHMeaning
< 7.35Acidemia
7.35–7.45Normal systemic arterial pH
> 7.45Alkalemia
< 6.7 or > 7.6Unsustainable: may cause cardiac hypocontractility/irritability, seizures, cerebral edema, metabolic disturbances; may warrant therapy to normalize serum pH along with treatment of the underlying cause
Slide 8’s 6.7 and 7.6 are the values tested.
Memory aid

The survival limits are mirror images: 6.7 and 7.6, the same two digits swapped.

Below 7.35 acidemia7.35–7.45 normalAbove 7.45 alkalemia6.7 / 7.6 unsustainable: may warrant therapy to normalize the pH, along with the cause

Where it breaks: The swap is lopsided: 6.7 sits 0.65 below the normal floor, 7.6 only 0.15 above the ceiling.

Simple Acid-Base Disorders: Expected CompensationCriteria · Lecture 34 · slides 22, 38, 59

Disorder (slide 59)Primary defectCompensatory responseMagnitude of compensation
Respiratory acidosis, acute↑ carbon dioxide↑ bicarbonate↑ bicarbonate 1 mEq/L per 10 mm Hg ↑ carbon dioxide
Respiratory acidosis, chronic↑ carbon dioxide↑ bicarbonate↑ bicarbonate 3.5 mEq/L per 10 mm Hg ↑ carbon dioxide
Respiratory alkalosis, acute↓ carbon dioxide↓ bicarbonate↓ bicarbonate 2 mEq/L per 10 mm Hg ↓ carbon dioxide
Respiratory alkalosis, chronic↓ carbon dioxide↓ bicarbonate↓ bicarbonate 5 mEq/L per 10 mm Hg ↓ carbon dioxide
Metabolic acidosis↓ bicarbonate↓ carbon dioxide↓ carbon dioxide 1.3 mm Hg per 1 mEq/L ↓ bicarbonate
Metabolic alkalosis↑ bicarbonate↑ carbon dioxide↑ carbon dioxide 0.75 mm Hg per 1 mEq/L ↑ bicarbonate
Slide 22: renal compensation for respiratory acidosis begins 6–12 hours after onset; complete compensation may take days. Slide 38: in metabolic alkalosis carbon dioxide is rarely above 55 mm Hg; if higher, consider a concurrent primary respiratory acidosis.
Slide 59 gives 3.5 for chronic respiratory acidosis; on the recording the lecturer rounded it to 4 for the math. Questions give these ratios when they are needed.
Memory aid

Respiratory: acid 1 then 3.5, alkali 2 then 5 (per 10, acute then chronic). Metabolic: acid 1.3, alkali 0.75 (per 1).

1 acute respiratory acidosis3.5 chronic respiratory acidosis2 acute respiratory alkalosis5 chronic respiratory alkalosis1.3 metabolic acidosis (carbon dioxide falls)0.75 metabolic alkalosis (carbon dioxide rises)

Where it breaks: Respiratory ratios are bicarbonate per 10 mm Hg of carbon dioxide; metabolic ratios flip to carbon dioxide per 1 mEq/L of bicarbonate. For the respiratory disorders, chronic is the bigger number (slide 22: renal compensation begins in 6–12 hours and may take days).

Is the Respiratory Compensation Appropriate?Criteria · Lecture 34 · slides 38, 58

DisorderExpected carbon dioxideIf the actual carbon dioxide is higher
Metabolic acidosis (slide 58)Winter’s formula: expected PaCO2 (arterial carbon dioxide) = 1.5 (measured bicarbonate) + 8 ± 2Metabolic acidosis together with respiratory acidosis; can be a sign of impending respiratory failure
Metabolic alkalosis (slide 38)Rises (decreased ventilation to retain carbon dioxide), rarely above 55 mm HgAbove 55: consider a concurrent primary respiratory acidosis
Memory aid

“One and a half, plus eight, give or take two”; and alkalosis tops out at 55.

1.5 × bicarbonate + 8 ± 2 expected carbon dioxide in metabolic acidosis55 the ceiling for compensation in metabolic alkalosis

Where it breaks: Both rows only flag a carbon dioxide that is too HIGH (added respiratory acidosis); the slides give no reading for one that is too low.

Anion GapCriteria · Lecture 34 · slides 47–49

ItemSlide wording
Formula (slide 47)Anion gap = sodium − (chloride + bicarbonate)
Normal (slide 47)9–15
Elevated (slide 48)Usually an increase in unmeasured anions; less often a decrease in unmeasured cations (calcium, magnesium, potassium, gamma-globulins)
Normal gap (slide 49)Does not exclude acidosis or a high unmeasured anion concentration; should not override clinical concern
Causes for error (slide 49)Hypoalbuminemia · hypernatremia/hyponatremia · antibiotics
Slide 47 prints the normal range as “9-15*”; the asterisk is not explained on the slide.
Memory aid

Sodium minus the two big anions, 9 to 15; and the gap lies when ASA: Albumin low, Sodium off, Antibiotics.

Na − (Cl + HCO3) sodium minus (chloride + bicarbonate)9–15 normalUp more unmeasured anions, or fewer unmeasured cationsNormal gap still may be acidosisA Albumin low (hypoalbuminemia)S Sodium high or lowA Antibiotics

Where it breaks: ASA is only the error list; the gap-raising cations (calcium, magnesium, potassium, gamma-globulins) are a separate list.

Elevated Anion Gap Metabolic Acidosis: MUDPILESCriteria · Lecture 34 · slides 54–55

LetterCause (slide 55)
MMethanol, metformin
UUremia
DDiabetic ketoacidosis
PParaldehyde
IIsoniazid, iron
LLactic acidosis
EEthylene glycol
SSalicylates, starvation
Slide 55: think about metabolic anions and drug/chemical anions. The slide spells “Isoniazide” and “Ethelyne glycol”.
Memory aid

MUDPILES (the slide’s own aid; its picture is a pile of mud).

M methanol, metforminU uremiaD diabetic ketoacidosisP paraldehydeI isoniazid, ironL lactic acidosisE ethylene glycolS salicylates, starvation

Where it breaks: Three letters carry two causes each (M, I, S): the second ones (metformin, iron, starvation) are the ones forgotten.

Normal Anion Gap Metabolic Acidosis: USEDCARCriteria · Lecture 34 · slides 54, 56

LetterCause (slide 56)
UUreteral diversion
SSaline infusion
EExogenous acid
DDiarrhea
CCarbonic anhydrase inhibitors
AAdrenal insufficiency
RRenal tubular acidosis
Slide 56: think about loss of bicarbonate, chloride retention, and acids (hydrochloric acid equivalents, ammonium chloride).
Memory aid

USEDCAR (the slide’s own aid; its picture is a rusted old truck).

U ureteral diversionS saline infusionE exogenous acidD diarrheaC carbonic anhydrase inhibitorsA adrenal insufficiencyR renal tubular acidosis

Where it breaks: Every letter is one cause; sort them by the slide’s three themes: bicarbonate lost (diarrhea, ureteral diversion, carbonic anhydrase inhibitors), chloride kept (saline), acid added (exogenous acid).

Metabolic Alkalosis: Saline Responsive vs UnresponsiveCriteria · Lecture 34 · slides 36–37, 41–44

TypeUrine chloride (slide 41)Causes (slides 42–43)Treatment (slide 44)
Saline responsive (more common): sign of extracellular volume contractionLower: < 25 mEq/LDiuretic therapy · post-hypercapnia · loss of hydrochloric acid (vomiting/nasogastric suction) · antacids · volume contractionTreat underlying cause; isotonic saline; discontinue diuretics
Saline unresponsive (elevated bicarbonate with euvolemia/hypervolemia, slide 37), normotensiveHigher: > 40 mEq/LSevere potassium depletion · hypoparathyroidism and hypercalcemiaTreat underlying cause
Saline unresponsive, hypertensiveHigher: > 40 mEq/LPrimary aldosteronism · exogenous alkali · mineralocorticoids · licoriceTreat underlying cause
Slide 43 files exogenous alkali (spelled “alkalai”) under the hypertensive group. Never decided by blood pressure group.
Memory aid

Under 25, saline revives; over 40, take the blood pressure. Hypertensive = MEAL.

< 25 saline responsive: give isotonic saline, stop diuretics> 40, normal pressure potassium depletion; hypoparathyroidism and hypercalcemiaM MineralocorticoidsE Exogenous alkaliA Aldosteronism (primary)L Licorice

Where it breaks: Urine chloride between 25 and 40 is not assigned on the slide. MEAL holds exogenous alkali only because slide 43 puts it there.

Suspected Acid-Base Disturbance: First SplitCriteria · Lecture 34 · slide 63 (picture s63-0dc2d8c2.png)

Arterial pHArterial carbon dioxideReadingNext step (slide 63)
< 7.4 (acidosis)> 40 mm HgRespiratory acidosisDetermine whether the lung disorder is acute or chronic
< 7.4 (acidosis)< 40 mm HgCompensation for metabolic acidosisCheck for ↑ anion gap; check clinical history for renal, gastrointestinal and systemic causes
> 7.4 (alkalosis)> 40 mm HgCompensation for metabolic alkalosisCheck clinical history for gastrointestinal, diuretic and antacid causes
> 7.4 (alkalosis)< 40 mm HgRespiratory alkalosisCheck clinical history for hyperventilation syndrome, drug and mechanical ventilator causes
Memory aid

ROME: Respiratory Opposite, Metabolic Equal.

Opposite, pH down pH below 7.4, carbon dioxide above 40: respiratory acidosisEqual, pH down both down: metabolic acidosis being compensatedEqual, pH up both up: metabolic alkalosis being compensatedOpposite, pH up pH above 7.4, carbon dioxide below 40: respiratory alkalosis

Where it breaks: ROME is an outside memory aid, not on the slide. The chart splits at the midpoints 7.4 and 40, not the normal ranges,; check the compensation with Winter’s formula and the compensation table.

pH Effects on Potassium & Oxygen DeliveryCriteria · Lecture 34 · slides 9–11 (picture s11-1da3bc9b.png)

StatePotassium (slide 9)Hemoglobin and oxygen (slides 10–11)
AcidosisHydrogen ions shift extracellular → intracellular; potassium shifts intracellular → extracellular → hyperkalemiaDecreased affinity of hemoglobin for oxygen → increased oxygen delivery to tissues; curve shifts right
AlkalosisHydrogen ions shift intracellular → extracellular; potassium shifts extracellular → intracellular → hypokalemiaIncreased affinity of hemoglobin for oxygen → decreased oxygen delivery to tissues; curve shifts left
Slide 11 picture, shift to the right: (1) increased hydrogen ions, (2) increased carbon dioxide, (3) increased temperature, (4) increased BPG (bisphosphoglycerate).
Memory aid

Acid pushes potassium Out and oxygen Off (Right = Release). Alkali pulls potassium In and Locks oxygen on (Left = Locked).

Acidosis → potassium out hyperkalemiaAlkalosis → potassium in hypokalemiaRight = Release acidosis: more oxygen to tissuesLeft = Locked alkalosis: less oxygen to tissuesRight-shifters hydrogen ions, carbon dioxide, temperature, bisphosphoglycerate: all increased

Where it breaks: Hydrogen and potassium always swap places: wherever hydrogen goes, potassium leaves.

Obesity Hypoventilation (Pickwickian) Syndrome TriadCriteria · Lecture 34 · slide 27

Triad feature (slide 27)
Obesity
Sleep disordered breathing
Chronic hypercapnia
Slide 27 lists it among the causes of chronic respiratory acidosis (with lung disease and neuromuscular disorders).
Memory aid

Heavy, snoring, holding carbon dioxide.

Heavy obesitySnoring sleep disordered breathingHolding carbon dioxide chronic hypercapnia

Where it breaks: “Snoring” stands for the slide’s broader “sleep disordered breathing”.

Classification of Asthma Severity (12 Years and Older)Criteria · Lecture 35 · slide 62 (picture s62-c725c812.png)

ComponentIntermittentMild persistentModerate persistentSevere persistent
Symptoms≤ 2 days/week> 2 days/week but not dailyDailyThroughout the day
Nighttime awakenings≤ 2×/month3–4×/month> 1×/week but not nightlyOften 7×/week
Short-acting beta-2 agonist use for symptom control (not prevention of exercise-induced bronchospasm)≤ 2 days/week> 2 days/week but not daily, and not more than 1× on any dayDailySeveral times per day
Interference with normal activityNoneMinor limitationSome limitationExtremely limited
Lung function: FEV1 (forced expiratory volume in 1 second) and its ratio to FVC (forced vital capacity)Normal FEV1 between exacerbations; FEV1 > 80% predicted; ratio normalFEV1 > 80% predicted; ratio normalFEV1 > 60% but < 80% predicted; ratio reduced 5%FEV1 < 60% predicted; ratio reduced > 5%
Risk: exacerbations requiring oral systemic corticosteroids0–1/year≥ 2/year≥ 2/year≥ 2/year
Slide 62 notes: severity is set by both impairment and risk; impairment is assessed by the patient’s recall of the previous 2–4 weeks and spirometry; assign severity to the most severe category in which any feature occurs. Patients with ≥ 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as persistent asthma, even without matching impairment.
The slide’s normal-ratio-by-age column and its treatment row are left out: the recording put them out of scope.
Memory aid

Intermittent plays the rule of twos; then symptoms go not-daily, daily, all day, and FEV1 drops past 80 and 60.

Symptoms ≤ 2 days → not daily → daily → all dayNights ≤ 2/month → 3–4/month → weekly, not nightly → often nightlyRescue inhaler ≤ 2 days → not daily → daily → several times a dayActivity none → minor → some → extreme limitationFEV1 > 80 (intermittent and mild) → 60–80 → < 60Steroid bursts 0–1/year intermittent; ≥ 2/year persistent

Where it breaks: Mild and intermittent share the same FEV1 (above 80% with a normal ratio): tell them apart by symptoms, nights and rescue use. Nights break the pattern too: intermittent counts per month, moderate per week.

Asthma Action Plan ZonesCriteria · Lecture 35 · slides 88–89 (pictures s88-59d3f609.png, s89-400e8d7c.png)

ZoneSignsPeak flow (slide 88)Action
Green: “Doing well” / GoSlide 88: no cough, wheeze, chest tightness, or shortness of breath during the day or night; can do usual activities. Slide 89 (all of these): breathing is good; no cough or wheeze; sleep through the night; can work and play≥ 80% of my best peak flowTake long-term control medicines each day (include an anti-inflammatory); slide 89: use preventive medicine
Yellow: “Asthma is getting worse” / CautionSlide 88: cough, wheeze, chest tightness, or shortness of breath; or waking at night due to asthma; or can do some, but not all, usual activities. Slide 89 (any of these): first signs of a cold; exposure to known trigger; cough; mild wheeze; tight chest; coughing at night50–79%Add quick-relief medicine (short-acting beta-2 agonist) and keep taking green zone medicine; slide 89: call your primary care provider
Red: “Medical alert!” / DangerSlide 88: very short of breath; or quick-relief medicines have not helped; or cannot do usual activities; or symptoms are same or get worse after 24 hours in yellow zone. Slide 89 (getting worse fast): medicine is not helping; breathing is hard and fast; nose opens wide; ribs show; can’t talk well< 50%Take quick-relief medicine and oral steroid, then call your doctor now; slide 89: get help from a doctor
Danger signs (slide 88)Trouble walking and talking due to shortness of breath; lips or fingernails are blue—Take 4 or 6 puffs of quick-relief medicine and go to the hospital or call an ambulance now
Memory aid

Traffic light at 80 and 50: green 80 and up, yellow 50–79, red under 50.

Green ≥ 80%, no symptoms day or night, usual activities: daily controllerYellow 50–79%, symptoms or night waking or some activities: add quick-reliefRed < 50%, very short of breath, quick-relief failing, or 24 hours in yellow without improvingDanger signs cannot walk and talk; blue lips or nails

Where it breaks: Slide 89’s traffic light has no percentages, and the danger signs are judged by sight, not by peak flow. Yellow that lasts 24 hours without improving becomes red.

Asthma Test Cut-OffsCriteria · Lecture 35 · slides 53, 58, 60, 94

TestCut-offMeaning
Spirometry before and after a bronchodilator (slide 53)FEV1 (forced expiratory volume in 1 second) improves ≥ 12%Supports asthma (before the bronchodilator: reduced FEV1 and reduced ratio)
Bronchial provocation: methacholine or histamine (slide 58)Not recommended if FEV1 < 65% predictedUseful if spirometry is not diagnostic; exercise challenge if exercise-induced bronchospasm is suspected
Peak expiratory flow at home (slide 60)20% change morning vs afternoon, or 20% change day to dayPoor control (measured in the morning before and the afternoon after the bronchodilator)
Exercise-induced bronchospasm (slide 94)Begins during or within 3 minutes after exercise; peaks in 10–15 minutes; resolves by 60 minutesCommon in children and adolescents
Slide 53 reads “FEV1 ≥12% or ≥ 10% improvement in predicted FEV1”; questions use the 12%.
Memory aid

Up 12 to diagnose, 65 is the floor for provoking, a 20% swing means poor control, and exercise runs on a 3-15-60 clock.

12 bronchodilator response that supports asthma65 no provocation test below 65% predicted20 peak flow swing (morning to afternoon or day to day) = poor control3-15-60 exercise bronchospasm: starts by 3, peaks 10–15, gone by 60 minutes

Where it breaks: The 15 in the clock is the top of a 10–15 minute peak, not a single time.

Extrinsic vs Intrinsic AsthmaCriteria · Lecture 35 · slides 34–35

FeatureExtrinsic (slide 35)Intrinsic (slides 34–35)
TriggerTriggered by allergen exposureNot triggered by allergen exposure
How commonMost common form of asthmaMinority (~10%)
Atopy and tests—Not atopic; negative skin allergy tests and normal serum IgE (immunoglobulin E)
Onset and course—Later onset (adulthood); usually more severe, persistent
Associations—Nasal polyps common; may be aspirin sensitive
PathologySame in bothSame in both
Memory aid

Intrinsic is the Late Adult with Polyps and Aspirin and clean allergy tests (LAPA).

Allergen extrinsic is triggered by it, intrinsic is notMost common extrinsic; intrinsic only about 10%Clean tests intrinsic: negative skin tests, normal IgEL, A Late onset in Adulthood, more severe and persistentP, A Polyps, Aspirin sensitivitySame pathology does not differ

Where it breaks: The slides describe intrinsic in detail and extrinsic only by its trigger and frequency; the dashes are blanks on the slides, not negatives.

Asthma: Risk of DeathCriteria · Lecture 35 · slide 14

Risk factor (slide 14)
Poorly controlled asthma: frequent bronchodilator use
No inhaled corticosteroids
Poor compliance with inhaled corticosteroids
Previous admissions for near-fatal attacks
Memory aid

Too much rescue, too little steroid (none or skipped), and a near-death before.

Too much rescue frequent bronchodilator useNone no inhaled corticosteroidSkipped poor compliance with the inhaled corticosteroidNear-death before previous admission for a near-fatal attack

Where it breaks: Two of the four are the same drug: the inhaled corticosteroid either never prescribed or not taken.

Atopic TriadCriteria · Lecture 35 · slide 25

Triad member (slide 25)
Allergic rhinitis
Asthma
Atopic dermatitis
Slide 25: atopy = genetic disposition for developing allergic reaction, with elevated IgE (immunoglobulin E) on exposure to allergen; non-atopic individuals have a low risk of asthma, and not all atopic individuals develop it.
Memory aid

Sneeze, wheeze, itch.

Sneeze allergic rhinitisWheeze asthmaItch atopic dermatitis

Where it breaks: Do not confuse it with the intrinsic picture (nasal polyps, aspirin sensitivity), which is not atopic.

Aspirin-Sensitive Asthma: Which Anti-Inflammatory DrugsCriteria · Lecture 35 · slide 93

Group (slide 93)Drugs
Avoid: non-selective NSAIDs (nonsteroidal anti-inflammatory drugs)Diclofenac · ibuprofen · naproxen · indomethacin
May use: selective NSAIDsCelecoxib · meloxicam
Memory aid

Avoid the DINI; you Can Manage with the selective two.

D diclofenacI ibuprofenN naproxenI indomethacinC celecoxibM meloxicam

Where it breaks: The slide lists brand names beside the selective drugs; only the generic names are used here.

Spirometry: Confirming the Diagnosis & Reading the PatternCriteria · Lecture 36 · slides 6, 26–27

FindingMeaning (slide wording)
Post-bronchodilator FEV1/FVC (forced expiratory volume in 1 second / forced vital capacity) < 0.70Confirms the diagnosis (slide 26); spirometry before and after a bronchodilator (albuterol) is required
FEV1 improvement of < 12% after bronchodilatorIrreversible airway obstruction: more likely chronic obstructive pulmonary disease than asthma (slide 26)
Is the FEV1 low? YesThe pattern is obstruction (slide 27)
Obstructed and FVC lowPossible mixed disorder, confirmed with TLC (total lung capacity)
FEV1/FVC normal and FVC lowPossible restriction, confirm with TLC
Chronic bronchitis without airflow obstructionIs NOT chronic obstructive pulmonary disease (slide 6)
Slide 27 opens with “Is the FEV1 low? If yes, the pattern is obstruction”; slide 26 and the grading table confirm the disease by the ratio below 0.70. Both are on the slides.
Memory aid

Seventy and twelve: under 0.70 confirms it, under 12% back means it stays.

< 0.70 ratio after a bronchodilator: confirms< 12% little bronchodilator response: irreversibleLow FEV1 obstructionLow FEV1 + low FVC maybe mixed: check total lung capacityNormal ratio + low FVC maybe restriction: check total lung capacityNo obstruction chronic bronchitis alone is not the disease

Where it breaks: Total lung capacity, not spirometry, settles both “possible” patterns.

Chronic Bronchitis vs Emphysema SubtypeCriteria · Lecture 36 · slides 6, 14

Feature (slide 14)Chronic bronchitis subtypeEmphysema subtype
DefinitionClinical: chronic productive coughPathologic: alveolar wall destruction and airspace enlargement
Primary siteLarge and small airways (mucus gland hyperplasia, goblet cells, wall thickening)Respiratory bronchioles and alveoli
PatternsMucus hypersecretionCentrilobular (smoking, upper lobes) vs panlobular (alpha-1 antitrypsin deficiency, lower lobes)
Mechanism of obstructionAirway narrowing and mucus pluggingLoss of elastic recoil, which causes airways to collapse on expiration
Classic descriptor“Blue bloater”“Pink puffer”
Typical examCough, sputum, rhonchi, possible cyanosis and edema (cor pulmonale)Thin, pursed-lip breathing, barrel chest, distant breath sounds, hyperresonance
Gas exchangeEarlier hypoxemia and hypercapniaRelatively preserved until late
DLCO (diffusing capacity of the lung for carbon monoxide)Normal or near normalReduced
ImagingBronchial wall thickeningHyperinflation, flat diaphragms, bullae; computed tomography shows emphysema
Slide 6: chronic bronchitis = chronic cough and sputum production, typically for at least 3 months per year for 2 consecutive years; emphysema = an anatomic, pathologic definition.
Memory aid

Blue Bloater = Bronchitis (big airways, Blocked by mucus); Pink Puffer = Parenchyma (alveoli Popped, recoil lost).

3 × 2 bronchitis: 3 months a year, 2 years runningBronchitis airways, mucus plugging, early low oxygen and high carbon dioxide, normal diffusing capacityEmphysema alveoli, lost recoil, gas exchange kept until late, reduced diffusing capacityUpper vs lower centrilobular = smoking, upper; panlobular = alpha-1 antitrypsin deficiency, lowerExam bloater: sputum, cyanosis, edema; puffer: thin, pursed lips, barrel chest

Where it breaks: Diffusing capacity is the cleanest single split: normal in bronchitis, reduced in emphysema.

Alpha-1 Antitrypsin Deficiency: When to Suspect & DiagnoseCriteria · Lecture 36 · slides 10, 12, 14, 19, 30

ItemSlide wording
Suggestive subsets (slide 19)Emphysema in a young individual (≤ 45 years) · emphysema in a nonsmoker or minimal smoker · emphysema predominantly basilar on chest x-ray · family history of emphysema
Pattern (slides 14, 19)Panlobular, lower lobes (slide 14); typically panacinar rather than the centracinar emphysema seen in smokers (slide 19)
Diagnostic (slide 30)Alpha-1 antitrypsin < 11 micromol/L with a severe deficient genotype
Slide 12: a genetic risk found in nonsmokers, about 3 or 4 cases per 10,000.
The age line differs by slide: slide 19 says 45 or younger, slide 10 says under 45. No question sits on exactly 45.
Memory aid

The “too” rule: too young, too clean, too low, too familial; and under 11 proves it.

Too young 45 or youngerToo clean nonsmoker or minimal smokerToo low basilar (lower-lobe, panlobular) emphysemaToo familial family history of emphysema< 11 micromol/L with a severe deficient genotype = diagnostic

Where it breaks: The level alone is not enough on slide 30: it needs the severe deficient genotype too.

GOLD Grades of Airflow ObstructionCriteria · Lecture 36 · slides 34–35 (pictures s34-0864f4e1.png, s35-bb932cdd.PNG)

GOLD (Global Initiative for Chronic Obstructive Lung Disease) gradeSeverityPost-bronchodilator FEV1 (forced expiratory volume in 1 second), % predicted
GOLD 1Mild≥ 80%
GOLD 2Moderate50% ≤ FEV1 < 80% (slide 35: 50–79)
GOLD 3Severe30% ≤ FEV1 < 50% (slide 35: 30–49)
GOLD 4Very severe< 30%
Slide 34: grades apply to patients with FEV1/FVC (forced vital capacity) < 0.7, based on the post-bronchodilator FEV1.
Memory aid

The grades fall at 80, 50 and 30: mild, moderate, severe, very severe.

1 mild, 80% and above2 moderate, 50–79%3 severe, 30–49%4 very severe, below 30%

Where it breaks: The steps are uneven (30 points, then 20), and the group is assigned from symptoms and exacerbations, not from the grade (slide 36 only says which grades are typical).

Modified MRC (Medical Research Council) Dyspnea ScaleCriteria · Lecture 36 · slide 24 (picture s24-4bd849a6.png)

GradeStatement (tick one box only)
0I only get breathless with strenuous exercise
1I get short of breath when hurrying on the level or walking up a slight hill
2I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level
3I stop for breath after walking about 100 meters or after a few minutes on the level
4I am too breathless to leave the house or I am breathless when dressing or undressing
In the group assessment (slides 35–37), grade ≥ 2 = more symptoms; 0–1 = fewer.
Memory aid

The walk shrinks each grade: Exercise, Hill, Peers, 100 meters, House.

Exercise 0: only strenuous exerciseHill 1: hurrying on the level or a slight hillPeers 2: slower than people my age, or stop at my own pace100 meters 3: stop after about 100 meters or a few minutesHouse 4: cannot leave the house, or breathless dressing

Where it breaks: Grade 2 has two ways in (slower than peers, or stopping at one’s own pace); it is also where “more symptoms” begins.

CAT (Chronic Obstructive Pulmonary Disease Assessment Test)Criteria · Lecture 36 · slide 23 (picture s23-cd2cd62a.png)

Item: 0 endItem: 5 end
I never coughI cough all the time
I have no phlegm (mucus) in my chest at allMy chest is completely full of phlegm (mucus)
My chest does not feel tight at allMy chest feels very tight
When I walk up a hill or one flight of stairs I am not breathlessWhen I walk up a hill or one flight of stairs I am very breathless
I am not limited doing any activities at homeI am very limited doing activities at home
I am confident leaving my home despite my lung conditionI am not at all confident leaving my home because of my lung condition
I sleep soundlyI don’t sleep soundly because of my lung condition
I have lots of energyI have no energy at all
Each item is scored 0–5 and summed. In the group assessment, total ≥ 10 = more symptoms, < 10 = fewer (slides 35–37). The slide 29 algorithm writes “CAT score >10”, and the slide 35 GOLD 2026 picture spells it “CAAT”.
Memory aid

Three chest, five life: cough, phlegm, tightness; then stairs, home, going out, sleep, energy. Ten or more = more symptoms.

Cough item 1Phlegm item 2Tightness item 3Stairs hill or one flightHome activities at homeGoing out confidence leaving homeSleep sleeps soundlyEnergy lots or none

Where it breaks: Only the cut-off of 10 is used for grouping; the slides give no other score bands.

GOLD 2020 Groups A–DCriteria · Lecture 36 · slides 35–36, 41 (picture s35-bb932cdd.PNG)

GroupExacerbation riskSymptoms
A: low risk, less symptoms0 or 1 exacerbation per year, no hospitalizationCAT < 10 or mMRC 0–1
B: low risk, more symptoms0 or 1 exacerbation per year, no hospitalizationCAT ≥ 10 or mMRC ≥ 2
C: high risk, less symptoms≥ 2 exacerbations per year or ≥ 1 hospitalizationCAT < 10 or mMRC 0–1
D: high risk, more symptoms≥ 2 exacerbations per year or ≥ 1 hospitalizationCAT ≥ 10 or mMRC ≥ 2
Slide 36 adds the airflow grade each group “typically” has; that line is never used to assign a group: groups come from symptoms and exacerbation history. CAT = chronic obstructive pulmonary disease Assessment Test; mMRC = modified Medical Research Council dyspnea grade.
Memory aid

“S × R = Group” (slide 41’s own aid): Symptoms across, Risk up.

A low symptoms, low riskB high symptoms, low riskC low symptoms, high riskD high symptoms, high risk

Where it breaks: The letters run like a grid read bottom row first (A, B), then the top row (C, D); 2023/2026 merges C and D into E.

GOLD 2023/2026 Groups A, B, E & Initial TreatmentCriteria · Lecture 36 · slides 35, 37, 40–41 (pictures s35-41b608bd.jpeg, s37-42529ad5.png, s37-a37313d0.png, s37-f9b1c17d.png)

GroupExacerbation history (per year)SymptomsInitial treatment (slide 37 Figure 4.2, slide 40)
A0 or 1 moderate exacerbations (not leading to hospital admission)mMRC 0–1, CAT < 10A bronchodilator (short- or long-acting)
B0 or 1 moderate exacerbations (not leading to hospital admission)mMRC ≥ 2, CAT ≥ 10LABA + LAMA (long-acting beta-2 agonist + long-acting muscarinic antagonist: dual bronchodilators)
E≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization (Figure 4.2, slide 40)AnyLABA + LAMA; consider LABA + LAMA + ICS (inhaled corticosteroid) if blood eosinophils ≥ 300
Slide conflict: the GOLD 2026 picture on slide 35 and the second picture on slide 37 define the high-risk (E) row as “One or more (≥ 1) moderate or severe exacerbations in the previous year” and A/B as “Zero (0)”; slide 36, slide 37’s Figure 4.2 and slide 40 say ≥ 2 moderate or ≥ 1 leading to hospitalization. Not resolved here.
Figure 4.2: single inhaler therapy may be more convenient and effective than multiple inhalers; the table is for initial treatment of patients naive to maintenance therapy (slide 37). The slide 35 picture spells the test “CAAT”.
Memory aid

A = A bronchodilator; B = Both bronchodilators; E = Exacerbator: both, plus a steroid if Eosinophils are 300 or more.

A few symptoms, low risk: one bronchodilatorB many symptoms, low risk: long-acting beta-2 agonist + long-acting muscarinic antagonistE high risk at any symptom level: the same pair ± inhaled corticosteroid300 blood eosinophil count that adds the inhaled corticosteroid

Where it breaks: Symptoms split only the low-risk row; E ignores them. Where the high-risk line sits (one exacerbation, or two or one hospitalization) differs between the slides: see the note.

Non-Pharmacologic Management by GroupCriteria · Lecture 36 · slides 43, 48 (picture s43-2d894642.png)

Patient group (Table 4.9)EssentialRecommendedDepending on local guidelines
ASmoking cessation (can include pharmacological treatment)Physical activityFlu, pneumococcal, pertussis, COVID-19 and shingles vaccinations
B and ESmoking cessation (can include pharmacological treatment); pulmonary rehabilitationPhysical activityFlu, pneumococcal, pertussis, COVID-19 and shingles vaccinations
Slide 48: every patient should get a yearly influenza shot (reduces hospitalizations and death); pneumococcal vaccine at age 65, earlier with severe disease (FEV1 (forced expiratory volume in 1 second) < 40%) or cardiac comorbidities. Vaccine product names are not used.
Memory aid

Everyone quits and moves; B and E also go to Rehab.

Quits smoking cessation: essential for allMoves physical activity: recommended for allRehab pulmonary rehabilitation: essential in B and E onlyFive shots flu, pneumococcal, pertussis, COVID-19, shingles per local guidelines

Where it breaks: The two rows differ by one cell only: pulmonary rehabilitation.

BODE Index PointsCriteria · Lecture 36 · slide 52 (picture s52-090be5c5.jpeg)

Variable0 points1 point2 points3 points
FEV1 (forced expiratory volume in 1 second), % of predicted≥ 6550–6436–49≤ 35
6-minute walk distance (meters)≥ 350“250-249” (see note)150–249≤ 149
mMRC (modified Medical Research Council) dyspnea scalemMRC 0–1mMRC 2mMRC 3mMRC 4
Body-mass index> 21≤ 21——
Slide 52 prints the 1-point walk band as “250-249”; between its neighbors it can only be 250–349. Questions avoid that band.
Memory aid

BODE = Body-mass index, Obstruction, Dyspnea, Exercise. Cut-offs: FEV1 65, 50, 35; walk 350, 250, 150; body-mass index 21.

B body-mass index: above 21 = 0, 21 or less = 1O obstruction (FEV1): 65 / 50–64 / 36–49 / 35 or lessD dyspnea (mMRC): 0–1, 2, 3, 4 → 0, 1, 2, 3 pointsE exercise (6-minute walk): 350 / 250 / 150 / 149 or less

Where it breaks: Body-mass index scores only 0 or 1, so the total runs 0–10. The dyspnea row is the mMRC grade minus one (0–1 both score 0).

BODE Score & Estimated 4-Year SurvivalCriteria · Lecture 36 · slide 52 (picture s52-090be5c5.jpeg)

BODE index score (total points)Estimated 4-year survival
0–280%
3–467%
5–657%
7–1018%
Memory aid

80, 67, 57, then off the cliff at 7: 18%.

0–2 80%3–4 67%5–6 57%7–10 18%

Where it breaks: The first three bands drop about 10 points each; the last band is wider (7–10) and the drop is far steeper.

Does This Patient Need Supplemental Oxygen?Criteria · Lecture 36 · slides 20, 63–64 (picture s64-b28a6a1c.png)

Situation (slide 64)Oxygen saturationDecision
Severe resting desaturation≤ 88% at restQualifies for LTOT (long-term oxygen therapy) > 15 h/day; cor pulmonale absent: titrate to goal > 89%; present: > 90%–92%
Moderate resting desaturation89%–93% at restNo indication for long-term oxygen
Severe exertional desaturation (mobile, exertional symptoms: exercise test)≤ 88% with exertionQualifies for long-term oxygen during exertion
Moderate exertional desaturation89%–93% on exertionNo indication for long-term oxygen
Nocturnal desaturation≤ 88% at night onlyEvaluate for OSA (obstructive sleep apnea) and screen for other etiologies
Slide 63: treat if arterial oxygen < 55 mm Hg or saturation < 88%; slide 64 uses ≤ 88%. Slide 63 also says societies disagree on the saturation target (88–92% vs 90% vs at least 90%); no target is tested.
Slide 20: may need oxygen acutely if saturation is below 95% on room air, but a baseline below 88% requires oxygen chronically.
Memory aid

Eighty-eight earns oxygen; 89 to 93 gets none; night-only dips mean look for sleep apnea.

≤ 88 at rest long-term oxygen more than 15 hours a day89–93 no long-term oxygen, at rest or on exertion≤ 88 on exertion oxygen during exertion≤ 88 at night only evaluate for obstructive sleep apneaGoal above 89%; 90–92% if cor pulmonale

Where it breaks: Exactly 88% qualifies on slide 64 (≤ 88) but not by slide 63’s wording (< 88).

Exacerbation: Admission & Intensive Care CriteriaCriteria · Lecture 36 · slides 56–57

LevelCriteria (slide wording)
Exacerbation (slide 56)Acute worsening of dyspnea, cough, or sputum over 14 days or less; > 80% can be managed outpatient
Admission (slide 57)Marked symptoms despite acute management (moving the patient into a severe category) · requires noninvasive ventilatory support (BiPAP, bilevel positive airway pressure) · new physical signs (edema, arrhythmia, unable to control secretions) · significant comorbidities with an exacerbation · age · lack of home or outpatient resources
Intensive care unit admission (slide 57)Hemodynamically unstable, major infection, or requiring invasive ventilatory support: sepsis, altered mental status, respiratory failure, respiratory acidosis, low arterial oxygen (< 40 mm Hg or 5.3 kPa)
Slide 57 writes the oxygen value as “PAO2”.
Memory aid

Admit when My Breathing Needs Care At Home-less; intensive care when Unstable, Infected, Intubated.

14 an exacerbation runs 14 days or less; over 80% stay outpatientM, B, N Marked symptoms, BiPAP needed, New signsC, A, H Comorbidities, Age, Home resources lackingU, I, I Unstable hemodynamics, major Infection, Invasive ventilation40 arterial oxygen below 40 mm Hg = intensive care

Where it breaks: Noninvasive support is an admission criterion; invasive support moves the patient to intensive care.

Exacerbation: When & Which AntibioticsCriteria · Lecture 36 · slide 59

Situation (slide 59)Choice
When to giveShortness of breath with increased sputum volume and purulence over baseline
Oral, uncomplicated (Haemophilus influenzae, strep, gram-positive)Doxycycline, macrolides, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanate
ResistanceRespiratory fluoroquinolones: levofloxacin or moxifloxacin
Pseudomonal concernLevofloxacin
Intravenous antibioticsSystemic or severe respiratory infection affecting oxygen saturation and other vitals (elevated lactate, white blood cells) · ventilation requiring support (noninvasive or invasive)
The slide names trimethoprim-sulfamethoxazole and amoxicillin-clavulanate by brand. Slide 59 also: some patients are put on long-term azithromycin or erythromycin (rare; raises resistance and side effects). Order on the slide: bronchodilators, oral corticosteroids, antibiotics, hospitalization.
Memory aid

Breathless + more + pus = antibiotics. Oral: Doxycycline, Macrolide, Trimethoprim-sulfamethoxazole, Amoxicillin-clavulanate (“Do More Than Amoxicillin”); resistance = a respiratory fluoroquinolone, Levofloxacin for pseudomonas.

More + pus increased sputum volume and purulence with dyspneaD, M, T, A the four oral first choicesResistance levofloxacin or moxifloxacinPseudomonas levofloxacinIntravenous sepsis-type vitals or labs, or ventilation support

Where it breaks: Levofloxacin appears twice: as a resistance choice and as the pseudomonal choice; moxifloxacin is only the former.

Discharge CriteriaCriteria · Lecture 36 · slide 60 (picture s60-2cf6fc4e.png)

Criterion (Table 1)
Able to use long-acting bronchodilators, either beta-2 agonists and anticholinergics with or without inhaled corticosteroids
Inhaled short-acting beta-2 agonist therapy is required no more frequently than every 4 hours
Patient, if previously ambulatory, is able to walk across room
Patient is able to eat and sleep without frequent awakening by dyspnea
Patient has been clinically stable for 12–24 hours
Patient (or home caregiver) fully understands correct use of medications
Follow-up and home care arrangements have been completed (visiting nurse, oxygen delivery, meal provisions)
Patient, family, and physician are confident that the patient can manage successfully at home
Consider pulmonary rehabilitation
Memory aid

2 drugs, 3 body checks, 4 plans.

Drug 1 on long-acting bronchodilatorsDrug 2 rescue inhaler no more than every 4 hoursBody 1 walks across the roomBody 2 eats and sleeps without waking breathlessBody 3 stable 12–24 hoursPlan 1 understands the medicinesPlan 2 follow-up and home care arrangedPlan 3 everyone confident at homePlan 4 consider pulmonary rehabilitation

Where it breaks: “Walk across the room” applies only if the patient walked before admission.

Referral to PulmonologyCriteria · Lecture 36 · slide 54

Reason (slide 54)
Diagnostic uncertainty
Early age of onset/suspected alpha-1 antitrypsin deficiency
Frequent exacerbations despite optimal therapy
Long-term oxygen therapy
Evaluation for noninvasive ventilation (continuous or bilevel positive airway pressure)
Possible surgical need
Symptoms out of proportion to pulmonary function tests
Slide 54, others: pulmonary rehabilitation, smoking cessation programs, pharmacist/respiratory therapist for inhaler review, palliative care, behavioral health.
Memory aid

Doctors You Find Often Need Surgical Skills.

D Diagnostic uncertaintyY Young onset / suspected alpha-1 antitrypsin deficiencyF Frequent exacerbations despite optimal therapyO long-term Oxygen therapyN Noninvasive ventilation evaluationS Surgical need possibleS Symptoms out of proportion to lung tests

Where it breaks: The “others” line (rehabilitation, cessation programs, pharmacist, palliative, behavioral health) is not in the aid.

Transtheoretical Model (Stages of Change)Criteria · Lecture 36 · slide 47 (picture s47-882a14b8.png)

StageDescriptionStatement
PrecontemplationNo intention to change behavior in the foreseeable future; often unaware of their problems“I do not think that I need to change any behaviors.”
ContemplationAware that a problem exists and seriously thinking about overcoming it; no commitment to take action“I’m concerned about my behavior, but not ready to make any changes now.”
PreparationExpressed intention to take action soon; reporting small behavioral changes“I’m ready to change my behavior now.”
ActionModify their behavior for a period from 1 day to 6 months“I’m changing my behavior now.”
MaintenanceContinue the change (usually > 6 months) and work to prevent relapse“I’ve changed my behavior.”
RelapseCessation of behavioral changes; revert to old behavior. Not a stage itself: a return from action or maintenance to an earlier stage“I’ve returned to my old behavior.”
Memory aid

Pre-Contemplate, Contemplate, Prepare, Act, Maintain; 6 months is the line between Action and Maintenance.

Pre no intention, unawareContemplate aware, thinking, not committedPrepare intends soon, small changesAct changing, 1 day to 6 monthsMaintain changed, more than 6 monthsRelapse a return, not a stage

Where it breaks: Preparation already shows small changes; it is the intent to act “soon” that keeps it before Action.

Respiratory Vaccines: Who Gets WhichCriteria · Lecture 37 · slides 4–13, 124

VaccineWhoWhen / how often
InfluenzaEveryone 6 months or older without a contraindication; 65+ preferentially high-dose, adjuvanted or recombinant; pregnancy inactivated or recombinant (no live attenuated)Every year; most adults September–October
COVID-19Adults 18+ (updated seasonal vaccine); immunocompromised from 6 months on a modified scheduleSeasonal; 65+ generally two doses about 6 months apart
Tdap (tetanus, diphtheria, acellular pertussis) / TdOne Tdap if no documented prior doseThen Td or Tdap every 10 years; Tdap every pregnancy, early in weeks 27–36
PneumococcalAll adults 50+; ages 19–49 with a risk conditionPCV20 or PCV21 (20- or 21-valent conjugate) alone, or PCV15 then PPSV23 (polysaccharide) usually 1 year or more later
RSV (respiratory syncytial virus)All 75+; 50–74 at increased risk; pregnancy 32–36 weeks (maternal vaccine)One dose; not annual
Hib (Haemophilus influenzae type b)Selected indications: asplenia without prior vaccination; after hematopoietic stem-cell transplantOne dose, preferably 14+ days before elective splenectomy; 3-dose series after transplant
Egg allergy needs no egg-free product or extra precautions (slide 6). The lecturer: vaccines “not a lot of detail on the exam”.
Memory aid

Every adult gets the FaCT; age and risk add the PRH.

F Flu, every yearC COVID-19, seasonal (65+ generally twice)T Tdap once, then every 10 years, and every pregnancyP Pneumococcal: 50+, or 19–49 with riskR RSV: once, 75+ or 50–74 at riskH Hib: asplenia or stem-cell transplant only

Where it breaks: Influenza starts at 6 months, not in adulthood; the FaCT is “every adult” only in the sense of slide 124.

Pneumococcal Vaccine: Risk Conditions at Ages 19–49Criteria · Lecture 37 · slide 10

GroupConditions listed on slide 10
HabitsAlcoholism · cigarette smoking
Holes and hardwareCerebrospinal fluid leak · cochlear implant
Organs failingChronic heart, liver or lung disease · chronic kidney failure · nephrotic syndrome
Immunity brokenHIV (human immunodeficiency virus) · immunodeficiency · immunosuppression · asplenia (no spleen) · sickle cell disease and other hemoglobinopathies · solid organ transplant · cancer
SugarDiabetes mellitus
Memory aid

HHOIS: two Habits, two Holes, failing Organs, broken Immunity, and Sugar.

H Habits: alcoholism, cigarette smokingH Holes and hardware: cerebrospinal fluid leak, cochlear implantO Organs: chronic heart, liver, lung disease; chronic kidney failure; nephrotic syndromeI Immunity: HIV, immunodeficiency, immunosuppression, asplenia, sickle cell and hemoglobinopathies, solid organ transplant, cancerS Sugar: diabetes mellitus

Where it breaks: The grouping is ours; the slide gives one long list, mostly alphabetical (sickle cell disease appears twice on it).

Pneumonia Types by Setting and TimingCriteria · Lecture 37 · slide 25

TypeDefinition (slide 25)
Community-acquired (CAP)Acquired outside the hospital or present early in admission; prior healthcare contact does not exclude it
Hospital-acquired (HAP)Develops 48 hours or more after admission; not incubating on admission
Ventilator-associated (VAP)Develops more than 48 hours after endotracheal intubation
Aspiration pneumoniaInfection after aspiration; community or hospital
The healthcare-associated (HCAP) category is retired: nursing-home residence or healthcare exposure alone does not mandate broad-spectrum therapy.
Memory aid

48 is the line: 48 hours or more after the door = HAP, more than 48 after the tube = VAP.

Before 48 h / outside CAP48 h after the door (admission) HAP48 h after the tube (intubation) VAPAfter aspiration, anywhere aspiration pneumonia

CURB-65: ItemsCriteria · Lecture 37 · slides 29, 31

LetterItem and cut-off (slide 31)Points
CConfusion: Abbreviated Mental Test Score 8 or less, or new disorientation to person, place or time+1
UUrea: blood urea nitrogen above 20 mg/dL (7 mmol/L)+1
RRespiratory rate 30 or more breaths per minute+1
BBlood pressure: systolic below 90 or diastolic 60 or less mmHg+1
65Age 65 or older+1
Memory aid

The name is the list: C-U-R-B-65, one point each, 0 to 5.

C ConfusionU Urea above 20 mg/dLR Respiratory rate 30 or moreB Blood pressure: systolic below 90 or diastolic 60 or less65 Age 65 or older

Where it breaks: Urea above 20 is strictly greater; respiratory rate 30 counts (30 or more).

CURB-65: Total, Severity and Where to TreatCriteria · Lecture 37 · slides 29, 31

TotalSeverity (risk of death)Where (slide 29 algorithm)
0–1Low (under 3%)Home with antibiotics, unless other reasons to admit (unstable comorbidity, social)
2Moderate (9%)Hospital: supportive care, microbiology, antibiotics
3–5High (15–40%)Hospital, urgent senior review; consider critical care, especially at 4 or 5
Slide 31: the Pneumonia Severity Index is preferred for admission support; CURB-65 complements, but does not replace, clinical judgment. Aim: diagnosis and antibiotics within 4 hours (slide 29).
Memory aid

0–1 go home, 2 come in, 3 or more call for help (4–5 think intensive care).

0–1 home2 hospital3–5 hospital plus senior review; intensive care at 4–5

Pneumonia Severity Index (PSI): Points and ClassesCriteria · Lecture 37 · slide 30 (pictures)

Finding (slide 30 calculator)Points
Female sex−10
Age1 per year
Nursing home resident+10
Neoplastic disease+30
Liver disease+20
Congestive heart failure+10
Cerebrovascular disease+10
Renal disease+10
Altered mental status+20
Respiratory rate 30/minute or more+20
Systolic blood pressure below 90 mmHg+20
Temperature below 35 °C or 40 °C or more+15
Pulse 125/minute or more+10
Arterial pH below 7.35+30
Classes: I = 0.1% mortality · II = 51–70 points, 0.6% · III = 71–90, 0.9% · IV = 91–130, 9.3% · V = 131–395, 27.0%
The slide’s calculator picture is cropped after arterial pH, and Class I has no point range on the slide; use the class table only with a given total.
Memory aid

Thirties are the killers (cancer, acid); twenties are the brain, lungs, pressure and liver; tens are the heart, stroke, kidney, home and pulse; women start 10 lower.

30 neoplastic disease, arterial pH below 7.3520 liver disease, altered mental status, respiratory rate 30+, systolic below 9015 temperature below 35 or 40+10 heart failure, cerebrovascular disease, renal disease, nursing home, pulse 125+−10 female sex+1/year ageClasses II 51–70, III 71–90, IV 91–130, V 131+

Where it breaks: Covers only the items visible on the slide; the full calculator continues past the crop.

Nonsevere vs Severe Community-Acquired PneumoniaCriteria · Lecture 37 · slide 45

NonsevereSevere
Severity signalNo major criterion and fewer than three minor criteriaVasopressor-dependent shock, mechanical ventilation, or at least three minor criteria
Place of carePneumonia Severity Index plus judgment: outpatient or general wardUrgent intensive-care-level assessment and support
TreatmentOutpatient or nonsevere inpatient regimen; resistant-pathogen coverage only for validated riskBeta-lactam combination regimen; cultures; resistant coverage only when risk supports it
DurationFewer than 5 days possible once stable, minimum 3At least 5 days and until clinically stable
The minor criteria are not listed anywhere on the slides; only the two major criteria are.
Memory aid

Severe = Squeezers or a Snorkel (or three minors); severe gets 5, nonsevere at least 3.

Squeezers vasopressor-dependent shockSnorkel mechanical ventilationThree minors at least three minor criteria3 and 5 minimum days: nonsevere 3, severe 5

Outpatient Community-Acquired Pneumonia: Empiric ChoiceCriteria · Lecture 37 · slide 43

Adult outpatientEmpiric treatment
No comorbidities, no MRSA (methicillin-resistant Staphylococcus aureus) or Pseudomonas riskAmoxicillin OR doxycycline; macrolide monotherapy only if local pneumococcal resistance is below 25%
Comorbidities: chronic heart, lung, liver or renal disease, diabetes, alcoholism, malignancy, asplenia (immunocompromised: separate assessment)Amoxicillin/clavulanate, cefpodoxime or cefuroxime PLUS azithromycin or doxycycline, OR a respiratory fluoroquinolone (levofloxacin or moxifloxacin); review allergy, QT, interactions, fluoroquinolone risks
Doses on the slide are left out here.
Memory aid

Healthy gets A or D; sick gets a beta-lactam with a Partner, or a Fluoroquinolone Flying solo.

A or D amoxicillin or doxycycline (macrolide alone only if resistance below 25%)Beta-lactam + Partner amoxicillin/clavulanate, cefpodoxime or cefuroxime plus azithromycin or doxycyclineFlying solo levofloxacin or moxifloxacin alone

Inpatient Community-Acquired Pneumonia: Empiric ChoiceCriteria · Lecture 37 · slide 44

Adult inpatientEmpiric treatment
Nonsevere, no MRSA (methicillin-resistant Staphylococcus aureus) or Pseudomonas riskBeta-lactam (for example ceftriaxone or ampicillin/sulbactam) plus a macrolide, OR respiratory fluoroquinolone monotherapy; beta-lactam plus doxycycline when macrolides and fluoroquinolones are unsuitable
Severe (intensive care evaluation: vasopressor-dependent shock or respiratory failure needing ventilation)Beta-lactam PLUS azithromycin or a respiratory fluoroquinolone; add MRSA or Pseudomonas coverage only for validated risks; cultures and de-escalation; severe beta-lactam allergy: review with pharmacy or infectious disease
Memory aid

Ward: BL + M or F alone (D if neither fits). Intensive care: BL + A or F, the beta-lactam always in.

BL + M beta-lactam plus macrolide (nonsevere)F alone respiratory fluoroquinolone monotherapy (nonsevere only)BL + D beta-lactam plus doxycycline when macrolide and fluoroquinolone are unsuitableBL + A or F severe: beta-lactam plus azithromycin or a fluoroquinolone

Hospital-Acquired and Ventilator Pneumonia: Empiric ChoiceCriteria · Lecture 37 · slides 40, 42, 46

Clinical situationTreatment approach
No major resistance or high mortality riskAntipseudomonal agent with MSSA (methicillin-sensitive S. aureus) coverage by the local antibiogram: piperacillin/tazobactam or cefepime
MRSA (methicillin-resistant S. aureus) risk, resistance risk or high mortality riskAdd vancomycin or linezolid for it; a second antipseudomonal class for selected high-risk patients; cultures, daily reassessment, de-escalation
DurationUsually 7 days if response is adequate
Moxifloxacin and ertapenem are not reliable Pseudomonas options (slide 40). Early or late timing alone does not select the regimen (slide 39).
Memory aid

Pip or Cef for Pseudomonas; V or L for MRSA; 7 days.

Pip or Cef piperacillin/tazobactam or cefepime (antipseudomonal backbone)V or L vancomycin or linezolid when methicillin-resistant S. aureus coverage is indicatedSecond class a second antipseudomonal class for selected high-risk patients7 usual duration in days

Pneumonia Patterns on the Chest FilmCriteria · Lecture 37 · slide 33 (picture)

PatternSignsUsual cause
LobarHomogeneous consolidation, silhouette sign, air bronchogram, sharply marginated fissureStreptococcus pneumoniae
BronchopneumoniaPoorly defined heterogeneous patchy infiltrates scattered through the lung; air bronchogramStaphylococcus aureus: multilobar, cavitation, pneumatoceles, abscess
InterstitialBilateral, diffuse fine reticular opacityPneumocystis jirovecii pneumonia
AspirationAirspace opacity in a lobar or segmental distribution; gravity-dependent predilectionStroke, seizure
The lecturer: the example films will not be shown on the exam as “what is it.”
Memory aid

Lobar Loves pneumococcus; Broncho Burrows (staph cavities); Interstitial = Immunocompromised (Pneumocystis); Aspiration falls Downhill after a stroke or seizure.

Lobar Streptococcus pneumoniaeBroncho Staphylococcus aureusInterstitial PneumocystisAspiration stroke, seizure; gravity-dependent

Pneumonia StagesCriteria · Lecture 37 · slide 26

StageWhat happens
1 CongestionExudate congests the alveoli and capillaries; the first 24 hours (later for atypicals)
2 Red hepatizationFibrin and red cells fill the area; no airflow; hyperemia
3 Gray hepatizationArea becomes avascular; leukocytes attack
4 ResolutionMacrophages clean up; airflow returns
The lecturer: “These aren’t cold, hard, fast rules.” Learn the order; the slide’s day ranges are not tested.
Memory aid

Cars Run Gray to Rust: Congestion, Red, Gray, Resolution.

C congestionR red hepatizationG gray hepatizationR resolution

Aspiration Pneumonitis vs Aspiration PneumoniaCriteria · Lecture 37 · slides 50–51

PneumonitisPneumonia
Core problemSterile chemical injury, often gastric contentsBacterial infection from colonized oropharyngeal material
PatternAbrupt decline after a witnessed aspiration; fever or leukocytosis can occur without infectionInfectious syndrome + infiltrate + aspiration risk; event may be unwitnessed
First stepSupport oxygenation and airway; no prophylactic antibiotics when bacterial infection is not suspectedCommunity- or hospital-acquired regimen by setting and severity
ReassessWorsening: secondary infection, complication or another diagnosisAnaerobic coverage only for abscess or empyema; address recurrent aspiration
Memory aid

-itis is Irritation (support it); -ia is Infection (antibiotics).

-itis chemical injury: support, no prophylactic antibiotics unless infection is suspected-ia bacterial infection: the community- or hospital-acquired regimenAnaerobes only for abscess or empyema

Risk Factors and Pathogens in Community-Acquired PneumoniaCriteria · Lecture 37 · slide 41 (picture)

Risk factorRelated pathogens
AlcoholismAnaerobic oral flora, Klebsiella pneumoniae, Mycobacterium tuberculosis, S. pneumoniae
AspirationAnaerobic oral flora
BioterrorismBacillus anthracis (anthrax), Francisella tularensis (tularemia), Yersinia pestis (plague)
Chronic obstructive pulmonary disease or smokingChlamydophila pneumoniae, Haemophilus influenzae, Legionella, Moraxella catarrhalis, Pseudomonas aeruginosa or other gram-negative rods, S. pneumoniae
Bat or bird droppingsHistoplasma capsulatum
Farm animals or parturient catsCoxiella burnetii (Q fever)
HIV, earlyH. influenzae, M. tuberculosis, S. pneumoniae
HIV, lateAspergillus, Cryptococcus, H. capsulatum, H. influenzae, Nocardia, nontuberculous mycobacteria, Pneumocystis jirovecii
Hotel or cruise ship travel in the past two weeksLegionella
Influenza active in the communityH. influenzae, influenza and other respiratory viruses, S. pneumoniae, Staphylococcus aureus (including methicillin-resistant strains)
Injection drug useAnaerobes, M. tuberculosis, S. aureus (including methicillin-resistant strains), S. pneumoniae
Lung abscessAnaerobic oral flora, M. tuberculosis, nontuberculous mycobacteria, S. aureus (including methicillin-resistant strains)
Middle EastMiddle East respiratory syndrome
Southeast and East AsiaAvian influenza, severe acute respiratory syndrome
Southeastern and south-central states bordering the Mississippi and Ohio River basinsBlastomyces dermatitidis
Southwestern United StatesCoccidioides, Hantavirus
Slide 75 places Histoplasma in the Ohio and Mississippi River valleys; this table ties those basins to Blastomyces. Exposure to droppings is the histoplasmosis clue.
Memory aid

Link each exposure to one picture: Booze, Barf, Bombs, Butts, Bats and Birds, Barns, the Body’s defenses early and late, Boats, Bugs going round, Needles, Cavities and the map.

Booze alcoholism: anaerobes, Klebsiella, tuberculosis, pneumococcusBarf aspiration: anaerobic oral floraBombs bioterrorism: anthrax, tularemia, plagueButts smoking or chronic obstructive pulmonary disease: Chlamydophila, Haemophilus, Legionella, Moraxella, Pseudomonas, pneumococcusBats and Birds HistoplasmaBarns farm animals or parturient cats: Coxiella (Q fever)Early HIV Haemophilus, tuberculosis, pneumococcusLate HIV Aspergillus, Cryptococcus, Histoplasma, Haemophilus, Nocardia, nontuberculous mycobacteria, PneumocystisBoats hotel or cruise travel: LegionellaBugs going round influenza season: Haemophilus, viruses, pneumococcus, S. aureus incl. methicillin-resistant strainsNeedles injection drug use: anaerobes, tuberculosis, S. aureus incl. methicillin-resistant strains, pneumococcusCavities lung abscess: anaerobes, tuberculosis, nontuberculous mycobacteria, S. aureusMap: Middle East Middle East respiratory syndromeMap: East Asia avian influenza, severe acute respiratory syndromeMap: Mississippi/Ohio basins BlastomycesMap: Southwest Coccidioides, Hantavirus

Where it breaks: A memory scaffold, not a rule: several pathogens repeat across rows, and pneumococcus sits in most of them.

Pneumocystis Pneumonia: Steroid and Prophylaxis ThresholdsCriteria · Lecture 37 · slides 71–73

DecisionThreshold (HIV-associated disease)
TreatmentTrimethoprim-sulfamethoxazole preferred, 21 days; intravenous for moderate to severe, then oral; check G6PD (glucose-6-phosphate dehydrogenase) before primaquine or dapsone
Add corticosteroidsRoom-air PaO2 (arterial oxygen) below 70 mm Hg, or alveolar-arterial gradient 35 mm Hg or more; start early, ideally within 72 hours
Start primary prophylaxisCD4 below 100 cells/mm³, or CD4 100–200 with detectable HIV RNA
Antiretroviral therapyStart within about 2 weeks of diagnosis when feasible
The lecturer: the alveolar-arterial gradient “is not going to show up on a test.”
Memory aid

70 for steroids, 100 for prophylaxis (200 if the virus is still detectable), 2 weeks to antiretrovirals.

70 room-air arterial oxygen below 70: add steroids100 CD4 below 100: prophylaxis100–200 + virus prophylaxis if HIV RNA detectable2 weeks start antiretroviral therapy

Influenza: High-Risk Groups (treat promptly, even after 48 hours)Criteria · Lecture 37 · slides 97–98

LetterHigh-risk group
PPregnancy in any trimester and the first 2 weeks postpartum
LLong-term care facility residents
IImmunocompromise from disease or treatment
CChronic pulmonary, cardiac, renal, hepatic, hematologic, metabolic or neurologic disease
OSevere obesity (and other CDC-listed conditions)
5Children younger than 5, especially younger than 2
65Adults 65 or older
Recent travel or animal exposure changes testing and public health needs but is not itself a universal severe-disease risk category (slide 98).
Memory aid

PLICO, 5 and 65.

P pregnancy and 2 weeks postpartumL long-term careI immunocompromiseC chronic organ diseaseO severe obesity5 under 565 65 or older

Influenza Antivirals: Who Gets WhichCriteria · Lecture 37 · slides 108–110

AgentUseAvoid / adjust
OseltamivirPreferred: hospitalized, severe or progressive, high-risk, pregnancy; start even after 48 hours; usual course 5 daysAdjust for renal function
BaloxavirSingle dose for uncomplicated influenza within 48 hours, age 5 or olderNot in pregnancy, breastfeeding, severe immunosuppression or hospitalized; no polyvalent cations together
Inhaled zanamivirOther optionAvoid in asthma or COPD (chronic obstructive pulmonary disease): bronchospasm
Intravenous peramivirEligible outpatients, uncomplicated influenzaAdjust for renal function
Amantadine, rimantadine—Not recommended (resistance)
Supportive care: avoid aspirin under 18 (Reye syndrome); antibiotics only for proven or suspected bacterial pneumonia (slide 110).
Memory aid

O is for Ordinary and the very sick; B is one-and-done but Bars the Bump, Breastfeeding, the Bedbound and the Badly immunosuppressed; Z wheezes; P needs kidneys checked; A and R are Retired.

O oseltamivir: preferred, pregnancy, hospitalizedB baloxavir: single dose; not pregnancy, breastfeeding, hospitalized, severe immunosuppressionZ zanamivir: avoid in asthma or COPDP peramivir: renal adjustmentA and R amantadine, rimantadine: resistance

COVID-19 Severity ClassesCriteria · Lecture 37 · slide 119

ClassCriteria
Asymptomatic or presymptomaticInfection without symptoms
MildSome symptoms, no dyspnea, normal chest film
ModerateSome symptoms, positive film, oxygen saturation at least 94% on room air
SevereSaturation below 94% on room air, marked tachypnea, infiltrates over 50% of lung volume
CriticalAcute respiratory failure, septic shock or multiple organ dysfunction
Memory aid

Film splits mild from moderate; 94 and 50 split moderate from severe; failure makes it critical.

None asymptomaticNormal film mildAbnormal film, 94%+ moderateBelow 94%, marked tachypnea, over 50% infiltrates severeFailure, shock, organs critical

COVID-19: Outpatient Antivirals vs Hospital TreatmentCriteria · Lecture 37 · slides 120–122

Early outpatient pathwayHospital pathway
WhoHigh-risk patient, mild or moderate disease, no hypoxemiaHypoxemia, severe respiratory disease or critical illness
TreatmentNirmatrelvir/ritonavir within 5 days or 3-day remdesivir within 7 days of onset; molnupiravir (adults) only if these are unsuitableDexamethasone; consider remdesivir by timing and support; baricitinib or tocilizumab plus steroids for rapid progression
ChecksDrug interactions, renal dosing, hepatic contraindications before nirmatrelvir/ritonavir; molnupiravir: avoid in pregnancyVenous thromboembolism prophylaxis unless contraindicated; therapeutic dosing needs a thrombosis and bleeding assessment, not D-dimer alone
AvoidNo systemic steroids without hypoxemia unless another indication—
Memory aid

N in 5, R in 7, M only as Last resort (never the Mother-to-be); Dexamethasone needs Desaturation.

N in 5 nirmatrelvir/ritonavir within 5 daysR in 7 remdesivir (3 days) within 7 daysM molnupiravir: last resort, avoid in pregnancyD dexamethasone only with hypoxemia

Psittacosis: Stages of ProgressionCriteria · Lecture 37 · slide 84

StageDescription
1Flulike syndrome without radiographic abnormalities
2Mild-to-moderate pneumonia
3Severe pneumonia
4Acute respiratory failure, sepsis and septic shock
Memory aid

Flu, Fair, Fierce, Failure.

Flu flulike, normal filmFair mild to moderate pneumoniaFierce severe pneumoniaFailure respiratory failure, sepsis, septic shock

Histoplasmosis and Cryptococcosis: Treatment by SeverityCriteria · Lecture 37 · slides 78, 123

Disease and severityTreatment
Histoplasmosis, mild acute, immunocompetent adultOften observation, not antifungals
Histoplasmosis, prolonged or progressive, or higher-risk hostConsider itraconazole (monitor interactions and levels)
Histoplasmosis, severe pulmonary or disseminatedSpecialist-led amphotericin-based induction
Histoplasmosis, chronic cavitaryProlonged azole, usually at least 12 months
Cryptococcosis, mild isolated pulmonaryFluconazole, generally 6–12 months
Cryptococcosis, severe pulmonary, central nervous system or disseminatedLiposomal amphotericin B plus flucytosine induction, then fluconazole; infectious disease consultation
Slide 78: the 2025/2026 updates replace a simple “4-week symptom” treatment rule for histoplasmosis.
Memory aid

Mild histo: Mind it (watch). Lingering: Itra. Life-threatening: Ampho. Crypto mild: Flu-con; crypto bad: Ampho + Flucytosine, then Flu-con.

Watch mild histoplasmosisItra prolonged or higher-risk histoplasmosisAmpho severe or disseminated histoplasmosis12 months chronic cavitary histoplasmosisFlu-con mild pulmonary cryptococcosisAmpho + flucytosine severe or central nervous system cryptococcosis

Pneumonia Testing: Only When It Changes a DecisionCriteria · Lecture 37 · slide 125

DecisionUseful testWhat changes
Is pneumonia present?Chest radiograph; lung ultrasound with expertiseConfirms a parenchymal process vs bronchitis or another diagnosis
Where to treat?Saturation, vital signs, organ dysfunction, sepsis assessment, Pneumonia Severity Index plus judgmentOutpatient vs ward vs intensive care
Will it change therapy or precautions?Molecular viral testing; cultures for severe community-acquired pneumonia or validated resistance riskAntivirals, infection prevention, targeted coverage, de-escalation
Atypical or complicated course?Computed tomography for uncertainty, cavitation, obstruction, abscess or empyema; targeted tests by exposure or immune statusDrainage, duration, consultation, organism-specific treatment
Memory aid

PAWS before you order: Present? Admit where? Would it change therapy? Strange course?

P is pneumonia present: filmA admit where: saturation, vitals, severity indexW would it change therapy: viral test, selective culturesS strange course: computed tomography, targeted tests

When to Withhold AntibioticsCriteria · Lecture 37 · slide 126

Withhold or stopDo not withhold
Uncomplicated acute bronchitis (whatever the sputum color or duration)Suspected bacterial pneumonia: community- or hospital-acquired pathway promptly
Chemical aspiration pneumonitis: supportive careSevere or unstable patient: specimens without delaying empiric therapy
Influenza or COVID-19 without bacterial complication: antiviral pathwayAspiration pneumonia, abscess or empyema (anaerobes for abscess or empyema)
Selected viral-positive outpatient community-acquired pneumonia, no comorbidities, close follow-upA worsening course: reassess, do not just add drugs
Antibiotics treat a bacterial syndrome, not cough duration, sputum color, a positive viral test or inflammation alone. Safety net: expected course, return precautions, a reassessment plan.
Memory aid

Hold for the 4 C’s that are not bacteria: Chest cold, Chemical burn, Corona or flu, a Clean viral outpatient. Give for the 4 S’s: Suspected bacteria, Sick or unstable, Suppuration (abscess, empyema, aspiration pneumonia), Sliding downhill.

Chest cold acute bronchitisChemical burn aspiration pneumonitisCorona or flu viral, no bacterial complicationClean viral outpatient viral-positive community-acquired pneumonia, no comorbidities, follow-upSuspected bacteria bacterial pneumoniaSick severe or unstableSuppuration aspiration pneumonia, abscess, empyemaSliding worsening course

Tuberculosis: StagesCriteria · Lecture 38 · slides 9–10, 12

StageWhat the slides say
Primary infectionInitial infection may remain contained without clinical disease
Progressive primary tuberculosisDisease develops soon after initial infection when immune containment fails
Latent tuberculosis infectionInfected but asymptomatic; not infectious, cannot spread it; no evidence of disease after evaluation
Reactivation (secondary) tuberculosisLatent infection progresses to disease, often with impaired immunity; reinfection is a separate event
Memory aid

Caught, Crashed early, Caged, Came back.

Caught primary infection, containedCrashed early progressive primary tuberculosisCaged latent infection: no symptoms, no spreadCame back reactivation (secondary), with impaired immunity

Latent Infection vs Tuberculosis Disease vs Nontuberculous DiseaseCriteria · Lecture 38 · slides 4, 10, 13, 16, 19, 23, 25–29, 33–34, 37–40

Latent tuberculosis infectionTuberculosis diseaseNontuberculous mycobacterial disease
SymptomsNonePersistent cough, fever, night sweats, weight loss (may be mild or absent)Chronic cough and sputum, fatigue, weight loss, dyspnea or hemoptysis
Spreads?NoYes if pulmonary or laryngeal (airborne)Person-to-person spread uncommon (environmental)
Skin or blood testPositive (shows infection only)Can be falsely negative (immunosuppression, severe tuberculosis); a negative never rules disease out—
Chest imagingUsually normalInfiltrates, cavities (upper lobes after primary), adenopathy, effusion, miliary nodulesNodular bronchiectasis or fibrocavitary disease on computed tomography
MicrobiologyNo evidence of disease3 sputum specimens: smear, culture, rapid molecular test, susceptibilitySame species in 2 or more sputum cultures, or 1 wash or lavage or biopsy
Treatment3HP, 4R or 3HR (6H or 9H if rifamycins unsuitable) after excluding disease2 months HRZE, then 4 months HR; isolation and notificationMacrolide-susceptible Mycobacterium avium complex: azithromycin, ethambutol, rifamycin, at least 12 months after culture conversion
An acid-fast smear cannot tell tuberculosis from nontuberculous mycobacteria (slide 4). Regimen letters are expanded in the regimen tables below.
Memory aid

Latent is Locked (no symptoms, no spread, normal film); Disease Disperses (symptoms, sputum, isolation); Nontuberculous comes from Nature (environment, needs repeat cultures).

Locked latent infectionDisperses tuberculosis diseaseNature nontuberculous mycobacterial disease

Risk of Progression After InfectionCriteria · Lecture 38 · slide 15

TierLetterRisk factor
HigherHHIV (human immunodeficiency virus) infection or major immunosuppression
HigherIImmunosuppressive treatment: TNF (tumor necrosis factor) inhibitors, transplantation, prolonged corticosteroids
HigherRRecent infection, especially within 2 years
HigherEEarly life: infancy and young childhood
AdditionalDDiabetes mellitus
AdditionalKChronic kidney disease or dialysis
AdditionalMSilicosis, low body weight or malnutrition (the lungs and the meal)
AdditionalSSmoking (tobacco) and harmful alcohol use
Memory aid

Higher risk HIREs it; Don’t Keep Missing Smokers.

H HIV or major immunosuppressionI TNF inhibitors, transplant, prolonged steroidsR recent infection within 2 yearsE infancy and young childhoodD diabetesK kidney disease or dialysisM silicosis, low weight, malnutritionS tobacco and harmful alcohol

Where it breaks: M packs three slide items (silicosis, low body weight, malnutrition) and S packs two (tobacco, alcohol).

Tuberculin Skin Test: Placing and ReadingCriteria · Lecture 38 · slides 20–21

StepRule (slide 20)
Place0.1 mL purified protein derivative intradermally on the forearm
ReadA trained reader at 48–72 hours
MeasureTransverse induration in millimeters; do not measure erythema
InterpretBy the patient’s risk category (the 5, 10, 15 mm table)
BCG (bacille Calmette-Guérin) historyCan cause a false-positive skin test; use the same thresholds regardless; interferon-gamma release assay preferred for most vaccinated patients (slide 21)
Memory aid

Point-one in, two to three days, feel the bump not the blush.

Point-one 0.1 mL intradermal, forearmTwo to three days read at 48–72 hoursBump not blush measure induration, not erythemaRisk group interpret by categoryBCG same thresholds; prefer the blood test

Tuberculin Skin Test: Positivity ThresholdsCriteria · Lecture 38 · slide 22 (focus slide 41 repeats the 5 mm line for HIV and recent close contact)

IndurationPositive in
5 mm or moreHIV, recent close contact, transplant, major immunosuppression, or imaging suggesting prior tuberculosis
10 mm or moreIncreased exposure risk, selected medical risks, high-risk congregate settings, children under 5 or children exposed to high-risk adults
15 mm or moreNo known tuberculosis risk factors
Memory aid

5 for the Sick and the Close, 10 for the Risky, 15 for the Rest.

5 immune-weak (HIV, transplant, immunosuppressed), close contacts, imaging suggesting prior tuberculosis10 exposure risk, medical risk, congregate settings, children under 515 no risk factors

Where it breaks: “Selected medical risks” is all the slide says for the 10 mm group; major immunosuppression is a 5 mm group.

When a Negative Test Does Not ReassureCriteria · Lecture 38 · slides 19, 23, 25 (focus slide 41 repeats the 8–10 week retest)

SituationWhat to do
Recent exposure (early infection)Repeat 8–10 weeks after the last exposure when indicated
Immunosuppression or severe tuberculosisFalse negatives possible
Symptoms or high clinical suspicionEvaluate for disease now; symptoms or suspicious imaging need microbiologic testing even with a negative skin or blood test
Young child or immunocompromised contactPrompt public-health assessment
Blood test indeterminate, invalid or borderlineRepeat it, or use a skin test
Blood test negativeInfection less likely, but disease still possible
Memory aid

Too Early, Too Weak, Too Sick, Too Young: a negative is not the end.

Too early repeat 8–10 weeks after exposureToo weak immunosuppression or severe tuberculosis: false negativeToo sick symptoms or high clinical suspicion: evaluate for disease nowToo young young or immunocompromised contacts: public health nowUnclear blood test repeat or use the skin testNegative blood test disease still possible

Skin Test vs Blood Test (Interferon-Gamma Release Assay)Criteria · Lecture 38 · slides 19–25

Tuberculin skin testInterferon-gamma release assay
DetectsImmune response to infectionImmune response to tuberculosis-specific antigens (blood)
Latent vs disease?Cannot tellCannot tell
BCG vaccineCan cause a false positiveDoes not cause a positive: preferred after BCG
VisitsPlacement, then a reading at 48–72 hoursOne visit
After treatmentMay stay positiveMay stay positive: monitor by clinical and microbiologic response
Memory aid

Both only say “infected”; the Blood test Beats BCG in one visit.

Infected only neither separates latent from diseaseBlood beats BCG no false positive after BCGOne visit blood testStays positive do not use either to monitor treatment

Suspected Pulmonary Tuberculosis: MicrobiologyCriteria · Lecture 38 · slide 26 (focus slide 41 repeats the first three rows)

StepRule
Collect3 sputum specimens, 8–24 hours apart, at least one early morning
Smear and cultureAcid-fast bacilli smear and mycobacterial culture
MolecularA rapid molecular test on at least one respiratory specimen
SusceptibilityMolecular and culture-based drug-susceptibility testing
HIVOffer HIV testing when status is unknown
Memory aid

3-8-1, then SMASH: 3 specimens, 8–24 hours apart, 1 in the morning; Smear (and culture), Molecular, Susceptibility, HIV.

3-8-1 3 specimens, 8–24 hours apart, 1 early morningS smear (and culture)M rapid molecular testS susceptibility testingH HIV test

Chest Imaging PatternsCriteria · Lecture 38 · slides 27–29

PictureTypical findings
Primary diseaseHilar or mediastinal adenopathy, infiltrates or effusion
Post-primary diseaseUpper lobes, may cavitate
Miliary diseaseDiffuse tiny nodules
HIV or other immunosuppressionAtypical patterns
Latent infectionUsually a normal film
Prior tuberculosisScarring, volume loss, calcified granulomas (review prior treatment, exclude active disease)
Imaging supports suspicion but cannot confirm tuberculosis or reliably determine activity, and cannot tell recent infection, reactivation or reinfection apart.
Memory aid

Primary Puffs the hilum; Post-primary Punches holes up top; Miliary is Millet seeds.

Primary hilar or mediastinal nodes, infiltrates, effusionPost-primary upper-lobe cavitiesMiliary diffuse tiny nodulesImmunosuppressed atypicalLatent normal filmOld scar, volume loss, calcified granulomas

Immediate Management of Pulmonary TuberculosisCriteria · Lecture 38 · slide 33 (focus slide 41 repeats the notify and airborne rows)

LetterAction
NNotify the local or state tuberculosis program of presumed or confirmed tuberculosis
AAirborne infection isolation room when indicated
NStaff wear a fit-tested N95 or higher-level respirator
SPatient source control during transport
EEnd isolation by clinical, laboratory and public-health criteria, not a fixed treatment interval
Memory aid

NANSE: Notify, Airborne room, N95, Source control, End by criteria.

N notify the programA airborne isolation roomN N95 respiratorS source control in transportE end by criteria, not by a calendar

Drug-Susceptible Tuberculosis: RegimensCriteria · Lecture 38 · slides 34–36

RegimenDrugs and length
Standard (slide 34)2 months HRZE: isoniazid (H), rifampin (R), pyrazinamide (Z), ethambutol (E); then 4 months HR; ethambutol stops once isoniazid and rifampin susceptibility is established; daily therapy with directly observed therapy (in person or by video) supports completion
17-week (slide 35)Age 12 or older, susceptible pulmonary disease: 8 weeks isoniazid, rifapentine, pyrazinamide, moxifloxacin; then 9 weeks isoniazid, rifapentine, moxifloxacin
Selected children, nonsevere (slide 35)4 months: 2 months isoniazid, rifampin, pyrazinamide (with or without ethambutol), then 2 months isoniazid and rifampin
Resistance and monitoring (slide 36)Rifampin resistance: rapid susceptibility testing and expert management; review at least monthly; sputum cultures until conversion, response documented at 2 months; watch liver injury, interactions, toxicity
Memory aid

RIPE for 2, then RI for 4; E Exits early once susceptibility is known.

R rifampinI isoniazid (H)P pyrazinamide (Z)E ethambutol, stops after susceptibility2 + 4 6 months total17 weeks 8 + 9, age 12 or older

Where it breaks: The slide writes the regimen as HRZE; RIPE is the same four drugs in a different order.

Latent Tuberculosis Infection: RegimensCriteria · Lecture 38 · slide 37

CodeRegimenUse
3HPWeekly isoniazid plus rifapentine for 3 monthsPreferred short regimen
4RDaily rifampin for 4 monthsPreferred short regimen
3HRDaily isoniazid plus rifampin for 3 monthsPreferred short regimen
6H or 9HIsoniazid for 6 or 9 monthsWhen rifamycin regimens are unsuitable
First exclude tuberculosis disease; check interactions, pregnancy considerations and source-case resistance.
Memory aid

The number is the months; H = isoniazid, R = rifampin, P = rifapentine; drop the rifamycin and the months go up (6H, 9H).

3HP 3 months, weekly isoniazid + rifapentine4R 4 months, daily rifampin3HR 3 months, daily isoniazid + rifampin6H / 9H isoniazid alone, rifamycin unsuitable

Nontuberculous Mycobacterial Lung Disease: Diagnosis and MAC TreatmentCriteria · Lecture 38 · slides 38–40 (focus slide 41 repeats the 2-culture rule and the three-drug regimen)

DomainRequirement
Symptoms and imagingCompatible symptoms and imaging (nodular bronchiectasis or fibrocavitary disease)
Something else excludedAlternative diagnoses excluded
Same speciesUsually 2 or more sputum cultures with the same species, or one positive bronchial wash or lavage or qualifying biopsy
MAC (Mycobacterium avium complex) treatmentMacrolide-susceptible: azithromycin, ethambutol and a rifamycin, at least 12 months after culture conversion; cavitary or severe: may need daily therapy and initial intravenous amikacin; still positive after 6 months or more: may warrant inhaled liposomal amikacin
A respiratory isolate alone does not prove disease (slide 38): all domains are required.
Memory aid

Three S’s to diagnose (Symptoms and Scan, Something else excluded, Same species twice); A-E-R for 12 after conversion.

S symptoms and scanS something else excludedS same species twice, or one wash, lavage or biopsyA-E-R azithromycin, ethambutol, rifamycin12 months after culture conversion

★ Professor Emphasized — Who Gets Oxygen, Who Qualifies, Fire

TermWhat you need to know
★ IndicationsHypoxia; acute medical or surgical needs (perioperative, postoperative); respiratory conditions (carbon monoxide poisoning); special indications without hypoxia: air hunger (end of life) and cluster headache. “One of the big things.”
★ FireBenefit: correction of hypoxia, symptom relief, therapeutic benefit. Risk: fire hazard — “probably one of the biggest risks.” Also hypercapnia (carbon dioxide retention), mucosal irritation, vasoconstriction.
Myocardial infarctionVasoconstriction: not given unless saturation is below 91% (the slide’s value; current guidelines use 90%).
★ Home qualificationDocumented hypoxia by arterial blood gas or pulse oximetry at rest, with exertion and/or during sleep, performed at the time of need. Rest: saturation ≤ 88% on room air or partial pressure of oxygen ≤ 55 mm Hg. Exertion: ≤ 88% and improves with oxygen. Sleep: ≤ 88% with a drop of 5% or more.
Group I vs IIGroup I (qualifies): ≤ 55 mm Hg or ≤ 88% → recertify at 12 months. Group II (conditional): 56–59 mm Hg or 89% plus pulmonary hypertension, cor pulmonale (right heart failure) or polycythemia (hematocrit above 56%) → recertify at 3 months.

Delivery Devices

TermWhat you need to know
Varies or fixedNasal cannula, simple mask: fraction varies with respiratory rate, inspiratory flow, tidal volume. Partial rebreather, non-rebreather: varies with patient demand. Air entrainment (Venturi, air-entrainment nebulizer): fixed, does not fluctuate.
Nasal cannulaLow flow, 1–6 L/min, 24–44% (room air 21%; about +4% per liter: 1 = 24, 2 = 28, 3 = 32, 4 = 36, 5 = 40, 6 = 44). Maxes at 44% even above 6 L/min. Humidity above 4 L/min. Mild hypoxia; most commonly used.
Simple maskLow flow, 5–10 L/min, .35–.50 (5–6 L/min 35%, 6–7 40%, 7–8 50%). Mild to moderate respiratory distress.
Partial rebreatherSome exhaled gas gets into the reservoir bag; not commonly used. Its fraction differs between slides (60–80% vs .40–.70): never tested.
Non-rebreatherLow flow device, but with a high fraction: 10–15 L/min = 60–100%. Reservoir bag + one-way valve (no inhaling exhaled air). Flow set to keep the bag from collapsing. Severely hypoxic patients still ventilating well.
Venturi maskHigh flow, precise; ports change the fraction; 4–10 L/min → 24–50%; total flow above inspiratory demand. Chronic obstructive pulmonary disease (precision).
Air-entrainment nebulizerAerosol mask, open face mask, T-piece, tracheostomy collar. Can deliver higher but not recommended above .50.
Advanced airwaysBag-valve mask (resuscitator bag); oropharyngeal and nasopharyngeal airways; endotracheal tube, tracheostomy; tube changer and bougie; laryngeal mask airway.

Nebulizers, Response & Education

TermWhat you need to know
Why a nebulizerLiquid medication directly to the airways; medication chosen for the specific treatment; secretion clearance; inhalers are challenging in certain situations; severe exacerbations of respiratory illness.
Is it working?Clinical: symptoms, work of breathing, color and perfusion. Objective: saturation improves (target varies); blood gas shows a higher oxygen without a higher carbon dioxide and a corrected pH. Vital signs; watch for complications.
★ Home safetyHighly flammable, compressed gas. No smoking; “No Smoking” and “Oxygen in Use” signs. At least 10 feet from heat sources (pilot lights, electric appliances, candles). No petroleum products (lip balms, lotions, oils, grease). Smoke and carbon monoxide alarms tested monthly. Proper storage and disposal.

★ Professor Emphasized — Normals, Winter Formula, Anion Gap

TermWhat you need to know
★ Normal valuespH 7.35–7.45 (“burn this into your eyeballs”); carbon dioxide 36–44 mm Hg (midpoint 40); bicarbonate 22–26 mEq/L (midpoint 24). Acidemia below 7.35, alkalemia above 7.45.
★ Winter formulaMetabolic acidosis: expected carbon dioxide = 1.5 × bicarbonate + 8, ± 2. Higher than expected = added respiratory acidosis, can signal impending respiratory failure.
★ Anion gapSodium − (chloride + bicarbonate), normal 9–15. Above 15 = elevated-gap acidosis.
★ Treatment“Always going to be correct the underlying disorder.” Therapy aimed at the pH itself only when it is unsustainable: below 6.7 or above 7.6.
★ Frequent questionsObesity hypoventilation triad; paper bag = placebo; saline responsive is the common alkalosis; carbon dioxide rarely above 55 in compensation; urine chloride splits the alkaloses.

Reading the Gas & Compensation

TermWhat you need to know
Steps1. pH: acidosis or alkalosis. 2. Which value (carbon dioxide or bicarbonate) matches the pH. 3. Mixed? pH more or less than expected. 4. Compensation: respiratory disorder → expected bicarbonate; metabolic disorder → expected carbon dioxide. 5. Don’t neglect the patient.
RulesCompensation never returns pH to normal and never past it; respiratory cause → renal compensation; metabolic cause → respiratory compensation. Normal pH with abnormal values = mixed disorder.
Ratios (given in questions)Respiratory acidosis: bicarbonate +1 per 10 mm Hg acute, +3.5 chronic. Respiratory alkalosis: −2 per 10 acute, −5 chronic. Metabolic acidosis: carbon dioxide −1.3 per 1 mEq/L (use Winter). Metabolic alkalosis: +0.75 per 1 mEq/L, rarely above 55 (above = concurrent respiratory acidosis).
TimingRenal compensation begins 6–12 hours after onset, complete over days: small bicarbonate change = acute, large = chronic.
AlgorithmpH below 7.4 + carbon dioxide above 40 = respiratory acidosis (acute or chronic?); below 40 = compensating metabolic acidosis (check the gap). pH above 7.4 + carbon dioxide above 40 = compensating metabolic alkalosis; below 40 = respiratory alkalosis.

Respiratory Acidosis & Alkalosis

TermWhat you need to know
Respiratory acidosisHypoventilation → carbon dioxide above 40 → low pH, ± hypoxemia. Somnolence, confusion, altered mental status, asterixis, myoclonus; severe: raised cerebral blood flow and intracranial pressure, papilledema. Labs: low pH, high carbon dioxide, high bicarbonate, hypochloremia if chronic (ammonium chloride excretion).
Acute causesAirway obstruction; pneumonia, asthma, pulmonary edema, aspiration pneumonitis; central nervous system depression (recreational drugs, intracranial catastrophe, intravenous sedation); myasthenia gravis, Guillain-Barré syndrome; pneumothorax, flail chest.
Chronic causesChronic obstructive pulmonary disease (“first thing that comes to mind”), interstitial lung disease, idiopathic pulmonary fibrosis; muscular dystrophy, amyotrophic lateral sclerosis; ★ obesity hypoventilation (Pickwickian) syndrome: obesity + sleep disordered breathing + chronic hypercapnia.
TreatUnderlying cause. Acute: restore ventilation. Chronic: careful oxygen titration; avoid rapid carbon dioxide reduction → post-hypercapnic metabolic alkalosis.
Respiratory alkalosisHyperventilation → low carbon dioxide → high pH. Light-headedness, anxiety, perioral numbness, paresthesias; severe: tetany (high pH binds calcium to albumin). Compensation: cells trade hydrogen ions for potassium, then kidneys excrete bicarbonate and keep chloride (low bicarbonate, hypokalemia, hyperchloremia).
Alkalosis causesPsychogenic, stroke, raised intracranial pressure; hypoxia (high altitude, severe anemia, ventilation-perfusion mismatch, hypotension); salicylates, caffeine, nicotine, catecholamines, thyroxine; pulmonary embolism, pneumonia, pulmonary edema, mechanical hyperventilation, interstitial lung disease; pregnancy, hyperthyroidism; septicemia, heat exposure, hepatic failure.
TreatUnderlying cause; usually self-limited. ★ Paper bag not necessary: does not correct carbon dioxide, may lower oxygen, placebo. Rapid correction of chronic alkalosis → post-hypocapnia metabolic acidosis.

Metabolic Alkalosis & Acidosis

TermWhat you need to know
Metabolic alkalosisHigh bicarbonate → high pH. No characteristic findings; orthostatic hypotension; hypokalemia → weakness, hyporeflexia. Labs: high pH and bicarbonate, raised carbon dioxide, low potassium, low chloride.
★ Urine chlorideBelow 25 mEq/L = saline responsive (more common; volume contraction): diuretics, post-hypercapnia, vomiting or nasogastric suction, antacids, volume contraction. Above 40 = saline unresponsive (euvolemic or hypervolemic) → check blood pressure.
Unresponsive groupsNormotensive: severe potassium depletion; hypoparathyroidism and hypercalcemia. Hypertensive: primary aldosteronism, exogenous alkali, mineralocorticoids, licorice (“a unicorn”).
Treat alkalosisUnderlying cause; saline responsive: isotonic saline and stop diuretics.
Metabolic acidosisLow bicarbonate → low pH, low carbon dioxide; hyperkalemia may be present. Signs of the cause + compensatory hyperventilation; Kussmaul respirations (increased tidal volume and tachypnea) in diabetic ketoacidosis. Normal gap = hyperchloremic; elevated gap = normochloremic.
Elevated gap: MUDPILESMethanol, metformin · uremia · diabetic ketoacidosis · paraldehyde · isoniazid, iron · lactic acidosis · ethylene glycol · salicylates, starvation.
Normal gap: USEDCARUreteral diversion · saline infusion · exogenous acid · diarrhea · carbonic anhydrase inhibitors · adrenal insufficiency · renal tubular acidosis (bicarbonate loss, chloride retention).
Gap pitfallsAlbumin makes most of the normal gap; hypoalbuminemia, sodium extremes and antibiotics distort it. A normal gap does not exclude acidosis and should not override clinical concern. Fewer unmeasured cations (calcium, magnesium, potassium) raise it.

Electrolytes & Oxygen

TermWhat you need to know
PotassiumAcidosis: hydrogen into cells, potassium out → hyperkalemia. Alkalosis: potassium into cells → hypokalemia.
OxygenAcidosis: lower hemoglobin affinity, curve right, more oxygen to tissues. Alkalosis: higher affinity, curve left, less oxygen to tissues.
Unsustainable pHBelow 6.7 or above 7.6: cardiac hypocontractility and irritability, seizures, cerebral edema, metabolic disturbances.
BuffersChemical buffering (extracellular, intracellular), respiratory (carbon dioxide, fast), renal (bicarbonate, hours to days). Water + carbon dioxide ↔ carbonic acid ↔ hydrogen ion + bicarbonate. Brainstem chemoreceptor: more carbon dioxide → lower cerebral pH → more breathing. Hypercapnia usually from under-excretion.

★ Professor Emphasized — Severity, Education, Classes

TermWhat you need to know
★ Severity from a descriptionTable for 12 years and older; severity goes to the most severe category in which any feature occurs. Intermittent = “rule of twos” (2 or fewer days/week, 2 or fewer nights/month). Focus on mild and moderate.
★ Persistent cut-offsMild: symptoms more than 2 days/week but not daily; 3–4 nights/month; 1-second volume above 80%. Moderate: daily; more than once/week but not nightly; 60–80%. Severe: all day; often 7/week; below 60%.
★ Patient educationWritten action plan; inhaler, spacer and nebulizer technique; peak flow zones; triggers; rinse the mouth after an inhaled steroid; vaccines. “Really important is the patient education.”
★ Classes, not brandsKnow the class: short-acting beta-2 agonist (rescue), inhaled corticosteroid (first-line controller), long-acting beta-2 agonist (never alone), leukotriene modifier (add-on).
Not testedEpidemiology numbers; emergency management (slides 97–105); age-normal ratio values; any question with conflicting rescue-inhaler guidance.

Definition, Types & Triggers

TermWhat you need to know
DefinitionChronic inflammatory airway disorder, reversible obstruction (some long-standing cases irreversible); trouble getting air out. Hyper-responsiveness: excessive constriction to a trigger a normal airway ignores.
CourseAny age, peak 3 years; may quiet in adolescence and return. Severity rarely changes: mild rarely becomes severe; severe usually severe at onset.
Death riskFrequent bronchodilator use; no or poorly taken inhaled steroid; previous near-fatal admission.
Extrinsic vs intrinsicExtrinsic: allergen-triggered, atopic, most common (atopic triad: rhinitis, asthma, eczema). Intrinsic: about 10%, adult onset, negative skin tests, normal immunoglobulin E, nasal polyps, may be aspirin sensitive.
Other typesOccupational (better weekends and vacations); catamenial (menstrual cycle); “cardiac” (decompensated heart failure); exercise-induced (starts within 3 minutes, peaks 10–15, gone by 60); aspirin-sensitive (1–5%, minutes to 12 hours).
TriggersDust mites (most common), pet dander, cockroaches, pollens, fungal spores; viruses; aspirin and beta blockers; exercise; cold air; pollution; smoke; stress; occupational agents.
Risk factorsAtopy; obesity (body mass index above 30); early viral infection. Allergen avoidance does not prevent asthma; early exposure may protect.

Diagnosis & Monitoring

TermWhat you need to know
ExamOften normal between attacks. Exacerbation: accessory muscles, leaning forward; wheeze may vanish (decreased breath sounds, prolonged expiration). Worse at night (peak 3–4 am).
SpirometryBefore and after a short-acting bronchodilator; reduced 1-second volume and ratio; 12% or more improvement supports asthma. Effort-dependent: coach. Repeat yearly.
Other testsProvocation (methacholine, histamine) if spirometry is not diagnostic, not below 65% predicted; exercise challenge for exercise-induced bronchospasm; allergy testing for triggers; exhaled nitric oxide = inflammation; chest x-ray normal or hyperinflated.
Peak flowHome baseline; morning before, afternoon after the bronchodilator; 20% change between them or day to day = poor control.
Action planGreen 80% or more of personal best; yellow 50–79% (add quick-relief, keep controller); red under 50%, very short of breath or quick-relief failing (medical alert). Danger signs: cannot walk or talk, blue lips or nails.
Visit sequenceInitial: diagnose, classify, start medicine and demonstrate, written plan, schedule follow-up. Follow-up: control, compliance, adjust, update plan.
DifferentialVocal fold dysfunction or paralysis, foreign body, laryngotracheal mass; chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis; conversion disorder, emotional laryngeal wheezing, factitious disorder; aspergillosis.
AspergillosisAllergic bronchopulmonary aspergillosis: hypersensitivity to Aspergillus fumigatus, almost only in asthma or cystic fibrosis; vigorous immunoglobulin E and G response; exacerbations.

Treatment by Class

TermWhat you need to know
RescueEvery patient needs a short-acting beta-2 agonist (albuterol); 3–6 hours; before exercise prevents exercise-induced bronchospasm; rising use = poor control; tremor, palpitations.
Inhaled corticosteroidPreferred first-line for persistent asthma; twice daily; full effect takes months; hoarseness, cough, thrush → spacer, rinse and spit.
Systemic steroidExacerbations: short course, no taper. Long-term only if refractory, minimum dose, with calcium and vitamin D. Side effects: truncal obesity, osteoporosis, bruising, ulcers, depression, hypertension.
Long-acting beta-2 agonistUp to 12 hours; never alone (no anti-inflammatory effect); pair with inhaled steroid.
Other controllersCromolyn: prevents, does not relieve. Tiotropium: slow, weak, few side effects. Theophylline: narrow range; nausea, vomiting, arrhythmias, seizures, high glucose, low potassium. Leukotriene modifiers: add-on, helpful for exercise-induced. Monoclonal antibodies: specialist, spare steroids.
AvoidAspirin and non-selective anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, indomethacin) in aspirin-sensitive asthma; selective ones (celecoxib, meloxicam) allowed. Beta blockers.
Immunotherapy & vaccinesImmunotherapy: allergic triggers, single allergen, controlled setting only. Influenza yearly and pneumococcal; caution with intranasal influenza vaccine.
Poor controlCheck compliance and technique first (most common reason); steroid resistance is very rare; refractory asthma → specialist.

★ Key Numbers

TermWhat you need to know
★ DiagnosisSpirometry before and after a bronchodilator: ratio of 1-second volume to forced vital capacity below 0.70; response under 12% = irreversible. Chronic bronchitis without obstruction is not this disease.
★ Airflow gradePost-bronchodilator 1-second volume: 1 mild ≥80%; 2 moderate 50–79%; 3 severe 30–49%; 4 very severe <30%.
★ Symptoms & riskAssessment test ≥10 or dyspnea grade ≥2 = more symptoms. High risk = 2 or more moderate exacerbations or 1 hospitalization.
★ Groups2020: A low/low, B high symptoms/low risk, C low symptoms/high risk, D high/high. 2023–2026: A, B, and E = any high risk. “S × R = group.”
★ StartA: one bronchodilator. B: long-acting beta agonist + long-acting antimuscarinic. E: that pair, add inhaled steroid if eosinophils ≥300.
★ SurvivalOnly smoking cessation, long-term oxygen (severe resting hypoxemia) and noninvasive ventilation (hypercapnic exacerbation) improve survival.

Subtypes, Causes & Presentation

TermWhat you need to know
DefinitionPersistent airflow obstruction + respiratory symptoms from inhaled particles; umbrella of chronic bronchitis (cough ≥3 months/year for 2 years) and emphysema (alveolar destruction).
Blue bloaterChronic bronchitis: sputum, rhonchi, cyanosis, edema; early hypoxemia and hypercapnia; normal diffusing capacity; bronchial wall thickening.
Pink pufferEmphysema: thin, pursed lips, barrel chest, distant sounds, hyperresonance; gas exchange late; reduced diffusing capacity; flat diaphragm, bullae.
CausesTobacco ~90% (primary); biomass smoke (low-income countries, never-smokers); coal, gold mining, welding; inactivity. Cessation is the key treatment.
Alpha-1 antitrypsin deficiencyAge ≤45, nonsmoker, basilar panlobular emphysema, family history; level <11 micromol/L + deficient genotype. Smokers: centrilobular, upper lobe.
Early signDyspnea on exertion. Not always thin; not always productive. Pursed lips keep airways open. Screen: heart disease, lung cancer, osteoporosis, depression, reflux, anemia.
Exam extrasFlat diaphragm → lower intercostal retraction on inspiration; neck veins distend in expiration; cor pulmonale; syncope and falls (poor perfusion).

Tests

TermWhat you need to know
PatternsLow ratio = obstruction. Obstruction + low forced vital capacity = possible mixed (confirm with total lung capacity). Normal ratio + low forced vital capacity = possible restriction.
PhysiologyAir trapping (residual volume up), hyperinflation, dynamic hyperinflation with exertion; scooped expiratory limb.
Other testsBlood gas only if deteriorating (carbon dioxide >45, bicarbonate up = compensatory metabolic alkalosis); blood count (anemia, eosinophils); B-type natriuretic peptide for heart failure; chest film rules out other causes; computed tomography rarely needed.
ScoresBODE (body mass index, obstruction, dyspnea, exercise) → 4-year survival: 0–2 = 80%, 3–4 = 67%, 5–6 = 57%, 7–10 = 18%. 1-second volume ≥65 = 0, 50–64 = 1, 36–49 = 2, ≤35 = 3; walk ≥350 m = 0, 150–249 = 2, ≤149 = 3; dyspnea 0–1 = 0, 2 = 1, 3 = 2, 4 = 3; body mass index ≤21 = 1.

Management

TermWhat you need to know
Non-drugCessation (essential, all groups, with counseling); rehabilitation essential for B and E; activity; yearly influenza vaccine; pneumococcal at 65 (earlier if 1-second volume <40% or cardiac disease).
Five A's / FRAMESAsk, Advise, Assess, Assist, Arrange. Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy.
Drug cautionsLong-acting beta agonist: arrhythmia, worse atrial fibrillation. Antimuscarinic: dry mouth, anticholinergic burden in elders. Inhaled steroid: never alone, pneumonia, fractures. Albuterol: not excessively. Oral steroids: exacerbations only.
Older adultsFixed 0.70 ratio may overdiagnose; arthritis, tremor, cognition, low flow limit dry powder inhalers → spacer, soft mist, nebulizer; refer to rehabilitation actively; palliative care early.
OxygenTreat arterial oxygen <55 mmHg or saturation <88%. Rest ≤88% → long-term oxygen >15 hours/day; rest 89–93% → none; exertion ≤88% → with exertion; night only → sleep apnea workup.
Refer to pulmonologyUncertain diagnosis, early onset or deficiency, exacerbations despite optimal therapy, oxygen, noninvasive ventilation, surgery, symptoms out of proportion.

Exacerbations

TermWhat you need to know
DefinitionAcute worsening over 14 days or less; exclude pneumonia, embolism, acute heart failure, pneumothorax. >80% outpatient.
Admit / intensive careAdmit: marked symptoms, noninvasive ventilation, new edema, arrhythmia, comorbidity, no home support. Intensive care: unstable, major infection, invasive ventilation, sepsis, altered mental status, acidosis.
TreatBronchodilators, steroids, oxygen; antibiotics if more and purulent sputum (doxycycline, macrolide, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate; levofloxacin for pseudomonal concern); high-flow for hypoxia; noninvasive ventilation for hypercapnia.
DischargeAlbuterol no more than every 4 hours; stable 12–24 hours; walks across room; eats and sleeps; home arrangements. Recovery 4–6 weeks.

★ Professor Emphasized — Restraint, Scores, Board Favorites

TermWhat you need to know
★ Study focus postedHe writes the exam items; his guidance is now slides 127–128 (the Study Focus table at the top of this sheet): about 20 questions on this lecture.
★ Diagnostic restraintBronchitis is “our first opportunity to practice diagnostic restraint”: no routine antibiotics, whatever the sputum color. He closed on testing only when it changes a decision, and when to withhold antibiotics.
★ ScoresPneumonia Severity Index preferred for admission; CURB-65 complementary (0:56).
★ Board favoritesHistoplasmosis (“going to show up on your PANCE”, the Physician Assistant National Certifying Exam); psittacosis (“super common medical boards question”).
Not tested (his words in the lecture)Example chest films as “what is it”; influenza vaccine make-up; stage day ranges; the alveolar-arterial gradient (but his focus slide now says “steroid thresholds”: know 35 mm Hg or more too). Vaccine product selection, RSV eligibility and pneumococcal sequencing ARE on his focus slide.

Acute Bronchitis

TermWhat you need to know
What it isSelf-limited viral infection of the large airways; cough (worst in the morning) 2–3 weeks, sometimes wheeze; clinical diagnosis.
ExamCentral wheeze; rhonchi that clear with cough; chest-wall tenderness; no consolidation (if present, think pneumonia).
TestsNo routine complete blood count, sputum culture or film; image if vital signs, focal findings or risk suggest pneumonia. Pertussis: test with paroxysms, post-tussive vomiting, whoop or exposure; don’t wait 4 weeks.
TreatExpectations, rest, fluids, acetaminophen (check combination products); no routine antibiotics, codeine or steroids; bronchodilator trial if wheezing. Delayed “pocket” prescription.
Return ifDyspnea, hemoptysis, persistent fever, hypoxemia, worse after improving.

Pneumonia: Workup & Treatment

TermWhat you need to know
Most common causeS. pneumoniae; highest incidence over 65; atypicals Mycoplasma, C. pneumoniae, Legionella (cruises, hot tubs, fountains).
PresentationHigher fever, chills, pleuritic pain, productive cough, tachypnea; one lobe of crackles, dullness, egophony (E to A), whispered pectoriloquy, increased fremitus.
ConfirmChest radiograph (ultrasound with expertise); cultures only for severe disease, resistance risk or failure; computed tomography for uncertainty, cavitation, non-homogeneous opacity, hidden lower lobes.
General careOxygen, fluids, sepsis care; narrow daily; no routine steroids in nonsevere pneumonia; steroids considered in severe community-acquired pneumonia except influenza pneumonia; drain complicated effusion or empyema.
Viral-positiveOutpatient without comorbidities: may skip antibiotics with close follow-up; with comorbidities or hospitalized: still treat.
Ventilator pneumoniaPseudomonas and multidrug-resistant organisms, higher mortality; prevent: early extubation, hand hygiene, sterile technique, fewer circuit changes, head of bed up, mouth care, secretion drainage.
PseudomonasMoxifloxacin and ertapenem are not reliable; MRSA: vancomycin or linezolid.

Aspiration & Lung Abscess

TermWhat you need to know
RiskDysphagia, altered consciousness, impaired airway protection (stroke, seizure); assess swallowing, oral hygiene, positioning.
Abscess pictureWeeks of fever, sweats, foul-smelling purulent sputum, hemoptysis; amphoric breath sounds (like breathing across an open jar); cavity with an air-fluid level.
Abscess treatmentStarts with antibiotics: intravenous ampicillin/sulbactam, then oral amoxicillin/clavulanate, several weeks; clindamycin reserved (C. difficile); computed tomography, bronchoscopy for obstruction or failure; drainage or surgery for large or refractory.

Fungal & Atypical

TermWhat you need to know
PneumocystisMost common opportunistic infection in HIV; exertional dyspnea and dry cough (95% each), fever; up to half normal exam; bilateral perihilar infiltrates. Induced sputum or bronchoalveolar lavage microscopy or polymerase chain reaction; negative induced sputum → lavage; lactate dehydrogenase nonspecific; treat while confirming if suspicion is high.
HistoplasmosisSoil, bird or bat droppings; Ohio and Mississippi River valleys; fever, dry cough, chest pain, headache 3–17 days later; urine antigen (cross-reacts with Blastomyces; repeat if early negative).
CryptococcosisEnvironmental inhalation; HIV, transplant, steroids, but also healthy hosts; mimics CAP, tuberculosis, cancer; serum cryptococcal antigen; lumbar puncture to look for central nervous system spread.
PsittacosisChlamydia psittaci from birds (pet shop, zoo, poultry); severe headache, photophobia, epistaxis, relative bradycardia, splenomegaly, Horder spots (rose-spot-like facial macules); nucleic acid amplification test or polymerase chain reaction (routine culture misses it); unilateral lower-lobe infiltrate. Doxycycline, 10–14 days after fever ends; macrolide with infectious disease if tetracyclines unsuitable; report to public health.
MycoplasmaChildren and young adults, outbreaks; gradual fever, persistent cough, headache. Macrolide or doxycycline (fluoroquinolone alternative); beta-lactams fail: no cell wall. No vaccine.

Influenza & COVID-19

TermWhat you need to know
Influenza basicsOrthomyxovirus, droplet nuclei; A most pathogenic; drift = gradual surface changes (yearly vaccine update), shift = reassortment (novel strains). Incubation 1–4 days; peaks mid-February.
Influenza pictureSudden onset; fever 100–104 °F, myalgias, frontal or retro-orbital headache, sore throat (why most seek care), red watery eyes.
Influenza testsMolecular preferred; a negative rapid antigen test does not exclude; don’t wait for results in hospitalized or high-risk patients; film in elderly or high-risk.
Influenza pneumoniaRapid cough, dyspnea, cyanosis; primary viral or secondary bacterial (pneumococcal or staphylococcal).
COVID-19 pictureInhaled particles indoors; incubation about 5 days; cough, dyspnea, fever, myalgia, headache; anosmia, dysgeusia less common; 18–33% asymptomatic.
COVID-19 testsNucleic acid amplification test (including polymerase chain reaction) most sensitive; negative antigen → repeat after 48 hours (2 tests if symptomatic, 3 if not) or a nucleic acid test; D-dimer alone does not diagnose thrombosis.

★ Professor Emphasized — Infection vs Disease

TermWhat you need to know
★ Three decisionsIs disease plausible? Could the patient be infectious? Which diagnostic and treatment pathway, and when to involve the health department or a specialist (3:09).
★ The distinctionInfection versus disease “determines infectiousness, evaluation, and treatment” (3:07): latent infection is asymptomatic and not infectious.
★ Study focus postedHis guidance is now slide 41 (the Study Focus table at the top of this sheet): about 10 questions on this lecture.
Watch outHe called fever and night sweats “pathognomonic”; the slide lists them as manifestations only, and symptoms may be absent.

Mycobacteria, Spread & Presentation

TermWhat you need to know
BiologyAcid-fast bacilli, lipid-rich walls with mycolic acids; slow growth (culture takes weeks, molecular tests are rapid); a smear cannot tell tuberculosis from nontuberculous species.
SpeciesM. tuberculosis complex (M. tuberculosis, M. bovis, M. africanum); nontuberculous: M. avium complex, M. kansasii, M. abscessus.
SpreadPulmonary and laryngeal disease, by coughing, speaking, singing; shared indoor air, poor ventilation. Latent infection does not spread; extrapulmonary usually does not.
Pulmonary diseasePersistent cough, hemoptysis or pleuritic pain, fever, night sweats, weight loss; don’t wait 3 weeks in high-risk patients; a normal exam does not exclude it; children, elders and the immunocompromised present atypically.
ExtrapulmonaryNodes (painless enlargement), pleura (effusion), central nervous system (headache, altered mental status), spine (back pain, vertebral destruction), disseminated (fever, weight loss).
DifferentialNontuberculous mycobacteria, bacterial pneumonia or abscess, histoplasmosis and other endemic fungi, bronchiectasis, aspergillosis, lung cancer and other cavities.

Treatment & Follow-Up

TermWhat you need to know
Before latent treatmentExclude disease; a positive skin or blood test still needs evaluation for disease.
During treatmentMonthly review of adherence, symptoms, adverse effects; liver injury; cultures until conversion; skin and blood tests may stay positive (don’t use them to monitor).
After tuberculosisPersistent dyspnea may be bronchiectasis; fibrotic lesions mean review prior treatment and exclude active disease; new symptoms mean reassess for recurrence.
NontuberculousRisk with bronchiectasis, chronic obstructive pulmonary disease, immune dysfunction; environmental; an isolate alone is not disease; other species need susceptibility-guided regimens.